Composition for improving symptoms of the eyes and / or nose and / or for preventing their onset or worsening.

Abstract

To provide a composition for improving symptoms of the eyes and / or nose and / or for preventing their onset or worsening. [Solution] A composition containing lactic acid bacteria for improving eye and / or nasal symptoms and / or preventing their onset or worsening.

Description

[Technical Field]

[0001] This disclosure relates to compositions for improving symptoms of the eyes and / or nose and / or for preventing their onset or worsening. [Background technology]

[0002] For individuals experiencing eye and / or nasal symptoms (including eye and nasal symptoms), quality of life (QOL) is significantly reduced. In Japan, in particular, large amounts of pollen from trees such as cedar and cypress are dispersed annually from February to May, resulting in a very high number of hay fever sufferers. For individuals experiencing or prone to eye and nasal symptoms, treatment with medications such as rhinitis drugs and eye drops is widely used to improve and prevent these symptoms.

[0003] On the other hand, Patent Document 1 discloses a food or beverage with anti-allergic function, characterized by the addition of Lactobacillus paracasei KW3110 strain or a mutant strain of Lactobacillus paracasei KW3110 strain having anti-allergic activity as an active ingredient. [Prior art documents] [Patent Documents]

[0004] [Patent Document 1] Japanese Patent Publication No. 2005-137357 [Overview of the Initiative] [Problems that the invention aims to solve]

[0005] This disclosure aims to provide compositions for improving symptoms of the eyes and / or nose and / or for preventing their onset or worsening. [Means for solving the problem]

[0006] The inventors have found that lactic acid bacteria and compositions containing them can improve eye and nasal symptoms and prevent their onset or worsening. Furthermore, through human trials, the inventors have found that lactic acid bacteria and compositions containing them are useful for improving certain eye and nasal symptoms and preventing their onset or worsening, and have demonstrated in particular that Lactobacillus paracasei KW3110, one of the lactic acid bacteria strains, and compositions containing it are useful for these purposes. In addition, through human trials, the inventors have identified suitable timings for initiating administration, administration regimens, and target populations for administering lactic acid bacteria and compositions containing them in order to improve eye and nasal symptoms and prevent their onset or worsening.

[0007] This disclosure relates, for example, to the following: <a1>A composition containing lactic acid bacteria for the improvement of eye and / or nasal symptoms and / or for the prevention of their onset or worsening. <a2>The above symptoms are symptoms experienced outdoors and / or during outdoor living. <a1>The composition described above. <a3>The above eye and / or nasal symptoms are sneezing fits and / or runny nose. <a1>or <a2>The composition described above. <a4>The improvement of the above symptoms is the alleviation of discomfort. <a1> ~ <a3>A composition as described in any one of the following. <a5>The above eye and / or nasal symptoms are those caused by hay fever. <a1> ~ <a4>A composition as described in any one of the following. <a6>5.0 x 10 per day for humans 10 pcs or more 3.0×10 11 The above lactic acid bacteria are characterized in that they are administered orally in quantities of one or fewer. <a1> ~ <a5>A composition as described in any one of the following. <a7>It is characterized by being used to be administered orally for a period of 28 days or more, starting from 28 days before the day when pollen dispersal begins and from before the day when pollen dispersal begins. <a1> ~ <a6>A composition as described in any one of the following. <a8>The maximum daily pollen count measured by the Durham method from the start of administration to day 28 of administration was 1 grain / cm³. 2 More than 220 pieces / cm 2 It is characterized by being used to be administered orally for the following period: <a1> ~ <a7>A composition as described in any one of the following. <a9>For use in patients with mild to moderate allergic ophthalmorhinoitis, <a1> ~ <a8>A composition as described in any one of the following. <a10>The lactic acid bacteria mentioned above is Lactobacillus paracasei. <a1> ~ <a9>A composition as described in any one of the following. <a11>The lactic acid bacteria mentioned above is Lactobacillus paracasei KW3110. <a1> ~ <a10>A composition as described in any one of the following. <a12>It is a food composition or a pharmaceutical composition. <a1> ~ <a11>A composition as described in any one of the following. <b1>A method for improving and / or preventing the onset or worsening of symptoms of the eyes and / or nose, including the administration of lactic acid bacteria. <b2>The above symptoms are symptoms experienced outdoors and / or during outdoor living. <b1>Methods used. <b3>The above eye and / or nasal symptoms are sneezing fits and / or runny nose. <b1>or <b2>Methods used. <b4>The improvement of the above symptoms is the alleviation of discomfort. <b1> ~ <b3>One of the following methods. <b5>The above eye and / or nasal symptoms are those caused by hay fever. <b1> ~ <b4>One of the following methods. <b6>5.0 x 10 per day for humans 10 pcs or more 3.0×10 11 Oral administration of the above lactic acid bacteria, <b1> ~ <b5>One of the following methods. <b7>The lactic acid bacteria are administered orally for a period of 28 days or more, starting from 28 days before the start of pollen dispersal and before the start of the pollen dispersal. <b1> ~ <b6>One of the following methods. <b8>The maximum daily pollen count measured by the Durham method from the start of administration to day 28 of administration was 1 grain / cm³. 2 More than 220 pieces / cm 2 The above lactic acid bacteria are administered orally for the following period: <b1> ~ <b7>One of the following methods. <b9>The above target group consists of individuals with mild to moderate allergic ophthalmorhinoitis. <b1> ~ <b8>One of the following methods. <b10>The lactic acid bacteria mentioned above is Lactobacillus paracasei. <b1> ~ <b9>One of the following methods. <b11>The lactic acid bacteria mentioned above is Lactobacillus paracasei KW3110. <b1> ~ <b10>One of the following methods. <b12>The above lactic acid bacteria are contained in a food composition or a pharmaceutical composition. <b1> ~ <b11>One of the following methods. <b13>The above subjects are human subjects. <b1> ~ <b12>One of the following methods. <b14>The above lactic acid bacteria are administered to those who need them. <b1> ~ <b13>One of the following methods. <b15>This includes improving the above-mentioned eye and / or nasal symptoms in the above-mentioned subjects. <b1> ~ <b14>One of the following methods. <c1>A method for improving and / or preventing the onset or worsening of symptoms of the eyes and / or nose, comprising administering a composition containing lactic acid bacteria to a subject. <c2>The above symptoms are symptoms experienced outdoors and / or during outdoor living. <c1>Methods used. <c3>The above eye and / or nasal symptoms are sneezing fits and / or runny nose. <c1>or <c2>Methods used. <c4>The improvement of the above symptoms is the alleviation of discomfort. <c1> ~ <c3>One of the following methods. <c5>The above eye and / or nasal symptoms are those caused by hay fever. <c1> ~ <c4>One of the following methods. <c6>Administer orally such that the above lactic acid bacteria are administered to a human at a dose of 5.0×10 10 or more and 3.0×10 11 or less per day. <c1> ~ <c5>One of the following methods. <c7>The above composition is administered orally for a period of 28 days or more, starting from 28 days before the day when pollen dispersal begins and before the day when pollen dispersal begins. <c1> ~ <c6>One of the following methods. <c8>The maximum daily pollen count measured by the Durham method from the start of administration to day 28 of administration was 1 grain / cm³. 2 More than 220 pieces / cm 2 The above composition is administered orally over the following period: <c1> ~ <c7>One of the following methods. <c9>The above target group consists of individuals with mild to moderate allergic ophthalmorhinoitis. <c1> ~ <c8>One of the following methods. <c10>The lactic acid bacteria mentioned above is Lactobacillus paracasei. <c1> ~ <c9>One of the following methods. <c11>The lactic acid bacteria mentioned above is Lactobacillus paracasei KW3110. <c1> ~ <c10>One of the following methods. <c12>The above composition is a food composition or a pharmaceutical composition. <c1> ~ <c11>One of the following methods. <c13>The above subjects are human subjects. <c1> ~ <c12>One of the following methods. <c14>The above composition is administered to subjects who require it. <c1> ~ <c13>One of the following methods. <c15>This includes improving the above-mentioned eye and / or nasal symptoms in the above-mentioned subjects. <c1> ~ <c14>One of the following methods. <d1>Lactobacillus for use in improving symptoms of the eyes and / or nose and / or preventing their onset or worsening. <d2>The above symptoms are symptoms experienced outdoors and / or during outdoor living. <d1>Lactic acid bacteria for use as described above. <d3>The above eye and / or nasal symptoms are sneezing fits and / or runny nose. <d1>or <d2>Lactic acid bacteria for use as described above. <d4>The improvement of the above symptoms is the alleviation of discomfort. <d1> ~ <d3>Lactic acid bacteria for use, as described in any one of the following. <d5>The above eye and / or nasal symptoms are those caused by hay fever. <d1> ~ <d4>Lactic acid bacteria for use, as described in any one of the following. <d6>5.0 x 10 per day for humans 10 pcs or more 3.0×10 11 The above lactic acid bacteria are used to be administered orally in quantities of one or fewer. <d1> ~ <d5>Lactic acid bacteria for use, as described in any one of the following. <d7>It is used to be administered orally for a period of 28 days or more, starting from 28 days before the start of pollen dispersal and before the start of the aforementioned pollen dispersal. <d1> ~ <d6>Lactic acid bacteria for use, as described in any one of the following. <d8>The maximum daily pollen count measured by the Durham method from the start of administration to day 28 of administration was 1 grain / cm³. 2 More than 220 pieces / cm 2 For the following periods, it is used to be administered orally: <d1> ~ <d7>Lactic acid bacteria for use, as described in any one of the following. <d9>It is administered to patients with mild to moderate allergic ophthalmorhinoitis. <d1> ~ <d8>Lactic acid bacteria for use, as described in any one of the following. <d10>The lactic acid bacteria mentioned above is Lactobacillus paracasei. <d1> ~ <d9>Lactic acid bacteria for use, as described in any one of the following. <d11>The lactic acid bacteria mentioned above is Lactobacillus paracasei KW3110. <d1> ~ <d10>Lactic acid bacteria for use, as described in any one of the following. <d12>The above lactic acid bacteria are contained in a food composition or a pharmaceutical composition. <d1> ~ <d11>Lactic acid bacteria for use, as described in any one of the following. <e1>A composition containing lactic acid bacteria for use in improving symptoms of the eyes and / or nose and / or preventing their onset or worsening. <e2>The above symptoms are symptoms experienced outdoors and / or during outdoor living. <e1>The composition for use described above. <e3>The above eye and / or nasal symptoms are sneezing fits and / or runny nose. <e1>or <e2>The composition for use described above. <e4>The improvement of the above symptoms is the alleviation of discomfort. <e1> ~ <e3>A composition for use as described in any one of the following. <e5>The above eye and / or nasal symptoms are those caused by hay fever. <e1> ~ <e4>A composition for use as described in any one of the following. <e6>5.0 x 10 per day for humans 10 pcs or more 3.0×10 11 The above lactic acid bacteria are used to be administered orally in quantities of one or fewer. <e1> ~ <e5>A composition for use as described in any one of the following. <e7>It is used to be administered orally for a period of 28 days or more, starting from 28 days before the start of pollen dispersal and before the start of the aforementioned pollen dispersal. <e1> ~ <e6>A composition for use as described in any one of the following. <e8>The maximum daily pollen count measured by the Durham method from the start of administration to day 28 of administration was 1 grain / cm³. 2 More than 220 pieces / cm 2 For the following periods, it is used to be administered orally: <e1> ~ <e7>A composition for use as described in any one of the following. <e9>It is administered to patients with mild to moderate allergic ophthalmorhinoitis. <e1> ~ <e8>A composition for use as described in any one of the following. <e10>The lactic acid bacteria mentioned above is Lactobacillus paracasei. <e1> ~ <e9>A composition for use as described in any one of the following. <e11>The lactic acid bacteria mentioned above is Lactobacillus paracasei KW3110. <e1> ~ <e10>A composition for use as described in any one of the following. <e12>The above composition is a food composition or a pharmaceutical composition. <e1> ~ <e11>A composition for use as described in any one of the following. <f1>The use of lactic acid bacteria in the improvement of eye and / or nasal symptoms and / or in the prevention of their onset or worsening. <f2>The above symptoms are symptoms experienced outdoors and / or during outdoor living. <f1>Use as described above. <f3>The above eye and / or nasal symptoms are sneezing fits and / or runny nose. <f1>or <f2>Use as described above. <f4>The improvement of the above symptoms is the alleviation of discomfort. <f1> ~ <f3>Use as described in any one of the following terms. <f5>The above eye and / or nasal symptoms are those caused by hay fever. <f1> ~ <f4>Use as described in any one of the following terms. <f6>5.0 x 10 per day for humans 10 pcs or more 3.0×10 11 The above lactic acid bacteria are administered orally in quantities of one or less. <f1> ~ <f5>Use as described in any one of the following terms. <f7>The lactic acid bacteria are administered orally for a period of 28 days or more, starting from 28 days before the start of pollen dispersal and before the start of the pollen dispersal. <f1> ~ <f6>Use as described in any one of the following terms. <f8>The maximum daily pollen count measured by the Durham method from the start of administration to day 28 of administration was 1 grain / cm³. 2 More than 220 pieces / cm 2 The above lactic acid bacteria are administered orally during the following period: <f1> ~ <f7>Use as described in any one of the following terms. <f9>The above-mentioned lactic acid bacteria are administered to individuals with mild to moderate allergic ophthalmorhinoitis. <f1> ~ <f8>Use as described in any one of the following terms. <f10>The lactic acid bacteria mentioned above is Lactobacillus paracasei. <f1> ~ <f9>Use as described in any one of the following terms. <f11>The lactic acid bacteria mentioned above is Lactobacillus paracasei KW3110. <f1> ~ <f10>Use as described in any one of the following terms. <f12>The above lactic acid bacteria are contained in a food composition or a pharmaceutical composition. <f1> ~ <f11>Use as described in any one of the following terms. <f13>It is a non-therapeutic use. <f1> ~ <f12>Use as described in any one of the following terms. <g1>Use of a composition containing lactic acid bacteria in the improvement of eye and / or nasal symptoms and / or prevention of their onset or worsening. <g2>The above symptoms are symptoms experienced outdoors and / or during outdoor living. <g1>Use as described above. <g3>The above eye and / or nasal symptoms are sneezing fits and / or runny nose. <g1>or <g2>Use as described above. <g4>The improvement of the above symptoms is the alleviation of discomfort. <g1> ~ <g3>Use as described in any one of the following terms. <g5>The above eye and / or nasal symptoms are those caused by hay fever. <g1> ~ <g4>Use as described in any one of the following terms. <g6>5.0 x 10 per day for humans 10 pcs or more 3.0×10 11 The above composition is administered orally so that the above lactic acid bacteria are administered in quantities of one or less. <g1> ~ <g5>Use as described in any one of the following terms. <g7>The composition is administered orally for a period of 28 days or more, starting from 28 days before the day when pollen dispersal begins and starting from the day when pollen dispersal begins. <g1> ~ <g6>Use as described in any one of the following terms. <g8>The maximum daily pollen count measured by the Durham method from the start of administration to day 28 of administration was 1 grain / cm³. 2 More than 220 pieces / cm 2 The above composition is administered orally during the following period: <g1> ~ <g7>Use as described in any one of the following terms. <g9>The above composition is administered to individuals with mild to moderate allergic ophthalmorhinoitis. <g1> ~ <g8>Use as described in any one of the following terms. <g10>The lactic acid bacteria mentioned above is Lactobacillus paracasei. <g1> ~ <g9>Use as described in any one of the following terms. <g11>The lactic acid bacteria mentioned above is Lactobacillus paracasei KW3110. <g1> ~ <g10>Use as described in any one of the following terms. <g12>The above composition is a food composition or a pharmaceutical composition. <g1> ~ <g11>Use as described in any one of the following terms. <g13>It is a non-therapeutic use. <g1> ~ <g12>Use as described in any one of the following terms. <h1>The use of lactic acid bacteria in the manufacture of compositions for improving symptoms of the eyes and / or nose and / or for preventing their onset or worsening. < / h1> <h2>The above symptoms are symptoms experienced outdoors and / or during outdoor living.< / h2> <h1>Use as described above. < / h1> <h3> The above eye and / or nasal symptoms are sneezing fits and / or runny nose.< / h3> <h1> or< / h1> <h2>Use as described above. < / h2> <h4> The improvement of the above symptoms is the alleviation of discomfort.< / h4> <h1>~< / h1> <h3>Use as described in any one of the following terms. < / h3> <h5> The above eye and / or nasal symptoms are those caused by hay fever.< / h5> <h1>~< / h1> <h4>Use as described in any one of the following terms. < / h4> <h6>The above composition is administered to humans at a dose of 5.0 × 10 per day. 10 pcs or more 3.0×10 11 This is intended for use in oral administration of the above lactic acid bacteria, with a quantity of one or fewer of the above-mentioned bacteria.< / h6> <h1>~< / h1> <h5>Use as described in any one of the following terms. <h7>The above composition is intended to be administered orally for a period of 28 days or more, starting from 28 days before the start of pollen dispersal and before the start of pollen dispersal. <h1>~< / h1> <h6>Use as described in any one of the following terms. <h8>The above composition has a maximum daily pollen count of 1 grain / cm³ measured by the Durham method from the start of administration to day 28 of administration. 2 More than 220 pieces / cm 2 It is intended to be administered orally for the following periods: <h1>~ <h7>Use as described in any one of the following terms. <h9>The above composition is intended for administration to individuals with mild to moderate allergic ophthalmorhinoitis. <h1>~ <h8>Use as described in any one of the following terms. <h10>The lactic acid bacteria mentioned above is Lactobacillus paracasei. <h1>~ <h9>Use as described in any one of the following terms. <h11>The lactic acid bacteria mentioned above is Lactobacillus paracasei KW3110. <h1>~ <h10>Use as described in any one of the following terms. <h12>The above composition is a food composition or a pharmaceutical composition. <h1>~ <h11>Use according to any one of the above.

Advantages of the Invention

[0008] According to the present disclosure, a composition for improving nasal and ocular symptoms and / or preventing the onset or exacerbation thereof is provided.

[0009] According to one aspect of the present disclosure, a lactic acid bacterium and a composition containing the same, which are suitable for improving a predetermined type of nasal and ocular symptoms and / or preventing the onset or exacerbation thereof, are provided.

[0010] According to one aspect of the present disclosure, an administration regimen of a lactic acid bacterium and a composition containing the same, which are suitable for improving nasal and ocular symptoms and / or preventing the onset or exacerbation thereof, is provided.

[0011] According to one aspect of the present disclosure, a composition and a timing of starting administration, which exhibit an excellent preventive effect on the onset or exacerbation of nasal and ocular symptoms particularly at the time when pollen starts to fly, are provided. The inventors have demonstrated by tests in humans that the onset or exacerbation of nasal and ocular symptoms at the time when pollen starts to fly is significantly prevented in subjects administered with the composition according to one aspect of the present disclosure.

Brief Description of the Drawings

[0012] [Figure 1] In the examples, it is a diagram showing the pollen scattering situation of Cryptomeria japonica and Chamaecyparis obtusa in Chiyoda-ku, Tokyo during the test period.

Modes for Carrying Out the Invention

[0013] Modes for carrying out the present disclosure will be described below, but the present disclosure should not be construed as being limited to the following embodiments.

[0014] <Lactic acid bacterium> Lactic acid bacteria are bacteria that produce lactic acid as a metabolite. Examples of lactic acid bacteria include those of the genera Oenococcus, Bifidobacterium, Weissella, Tetragenococcus, Lactococcus, Leuconostoc, Pediococcus, Streptococcus, Enterococcus, Lactobacillus, acetic acid bacteria, and Bacillus.

[0015] In this specification, the genus Lactobacillus includes bacteria that were classified under the genus Lactobacillus before the reclassification of the genus Lactobacillus. For example, following the reclassification of the genus Lactobacillus, the genera Acetilactobacillus, Agrilactobacillus, Amylolactobacillus, Apilactobacillus, Bombilactobacillus, Companilactobacillus, Dellaglioa, Fructilactobacillus, and Furfurilactobacillus were newly included. ) genus, Holzapfelia genus, Lacticaseibacillus genus, Lactiplantibacillus genus, Lapidilactobacillus genus, Latilactobacillus genus, Lentilactobacillus genus, Levilactobacillus genus, Ligilactobacillus genus, Limo This includes bacteria classified under genera such as Limosilactobacillus, Liquorilactobacillus, Loigolactobacillus, Paralactobacillus, Paucilactobacillus, Schleiferilactobacillus, and Secundilactobacillus.

[0016] Among the above, bacteria of the following genera are preferred: Oenococcus, Bifidobacterium, Lentilactobacillus, Weissella, Tetragenococcus, Lactococcus, Leuconostoc, Pediococcus, Enterococcus, Lactobacillus, and Lactiplantibacillus.

[0017] While not limited to specific species, the genus Oenococcus includes, for example, Oenococcus oeni. A specific example of an Oenococcus species is Oenococcus oeni JCM6125.

[0018] Examples of Bifidobacterium species include, but are not limited to, Bifidobacterium animalis subsp. lactis, Bifidobacterium pseudolongum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum subsp. longum, and Bifidobacterium longum subsp. infantis. Specific examples of Bifidobacterium species include Bifidobacterium animalis subspecies lactis JCM 10602, Bifidobacterium animalis subspecies lactis BB-12, Bifidobacterium longum subspecies infantis JCM 1222, Bifidobacterium longum subspecies infantis M-63, Bifidobacterium longum subspecies longum BB536, Bifidobacterium longum subspecies longum N61, Bifidobacterium bifidum OLB6378, Bifidobacterium breve M-16V, Bifidobacterium breve MCC1274, and Bifidobacterium pseudolongum JCM1205.

[0019] Weissella species are not limited to those listed, but examples include Weissella paramesenteroides and Weissella viridecens. Specific examples of Weissella species include Weissella paramesenteroides JCM 9890 and Weissella viridecens JCM 1174.

[0020] While not particularly limited, examples of Tetragenococcus species include Tetragenococcus halophilus. Specific examples of Tetragenococcus species include Tetragenococcus halophilus NRIC 0098 and Tetragenococcus halophilus No. 1.

[0021] Examples of Lactococcus species include Lactococcus lactis, Lactococcus lactis subsp. lactis, Lactococcus garvieae, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. hordniae, and Lactococcus plantarum.

[0022] Specific examples of Lactococcus species include Lactococcus lactis subspecies lactis JCM 5805, Lactococcus lactis subspecies lactis NBRC 12007, Lactococcus lactis subspecies lactis NRIC 1150, Lactococcus lactis subspecies lactis JCM 20101, Lactococcus lactis subspecies lactis JCM 7638, Lactococcus lactis subspecies lactis ATCC 7963, Lactococcus lactis subspecies lactis ATCC 7962, Lactococcus lactis subspecies lactis ATCC 29146, and Lactococcus lactis subspecies lactis ATCC 27861, Lactococcus lactis subspecies lactis ATCC 19435, Lactococcus lactis subspecies lactis ATCC 15577, Lactococcus lactis subspecies lactis ATCC 15346, Lactococcus lactis subspecies lactis ATCC 13675, Lactococcus lactis subspecies lactis ATCC 12929, Lactococcus lactis subspecies lactis ATCC 11955, Lactococcus lactis subspecies lactis ATCC 11454, Lactococcus lactis subspecies lactis ATCC 11007, Lactococcus garvieae NBRC Examples include Lactococcus lactis subspecies cremoris JCM 100934, Lactococcus lactis subspecies cremoris NBRC 100676, Lactococcus lactis subspecies heldniae JCM 1180, Lactococcus lactis subspecies heldniae JCM 11040, and Lactococcus plantarum JCM 11056.

[0023] Examples of Leuconostoc species include Leuconostoc carnosum and Leuconostoc lactis. Specific examples of Leuconostoc species include Leuconostoc carnosum JCM 9695 and Leuconostoc lactis NBRC 12455.

[0024] Examples of species belonging to the genus Pediococcus include, but are not limited to, Pediococcus acidilactici, Pediococcus pentosaceus, Pediococcus cellicola, Pediococcus claussenii, Pediococcus damnosus, Pediococcus ethanolidurans, Pediococcus inopinatus, Pediococcus parvulus, and Pediococcus stilesii. Specific examples of Pediococcus species include Pediococcus acidilactici JCM 8797, Pediococcus acidilactici K15, and Pediococcus damnosus JCM 5886.

[0025] Examples of Streptococcus species include, but are not limited to, Streptococcus thermophilus. Specific examples of Pediococcus species include, for example, Streptococcus thermophilus SBC 8781.

[0026] Enterococcus species are not limited to these, but examples include Enterococcus alcedinis and Enterococcus faecalis. A specific example of an Enterococcus species is Enterococcus faecalis EC-12.

[0027] While not particularly limited to Lactobacillus species, examples include Lactobacillus paracasei, Lactobacillus delbrueckii, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus fructivorans, Lactobacillus hilgardii, Lactobacillus rhamnosus, Lactobacillus gasseri, Lactobacillus acidophilus, and Lactobacillus bulgaricus. Examples include Lactobacillus bulgaricus, Lactobacillus parakefiri, Lactobacillus plantarum, and Lactobacillus pentosus.

[0028] Specific examples of Lactobacillus species include Lactobacillus paracasei (reclassified as Lacticaseibacillus paracasei) KW3110, Lactobacillus paracasei MCC1849, Lactobacillus paracasei K71, Lactobacillus paracasei K-2, Lactobacillus rhamnosus GG, Lactobacillus rhamnosus CRL1505, Lactobacillus gasseri SBT2055, Lactobacillus gasseri OLL2716, Lactobacillus gasseri PA-3, Lactobacillus acidophilus L-92, Lactobacillus casei subspecies casei 327, Lactobacillus casei Shirota (reclassified as Lacticaseibacillus casei), Lactobacillus bulgaricus OLL1073R-1, and Lactobacillus bulgaricus. Examples include Lactobacillus parachephyri (Lentilactobacillus parachephyri in the new classification) JCM 8573, Lactobacillus plantarum (Lactiplantybacillus plantarum in the new classification) L-137, and Lactobacillus pentosus (Lactiplantybacillus pentosus in the new classification) ONRICb0240.

[0029] The acetic acid bacteria are not particularly limited, but examples include bacteria of the genus Gluconacetobacter, Acetobacter, and Gluconobacter, with Gluconacetobacter being preferred, Gluconacetobacter hanzenii being more preferred, and Gluconacetobacter hanzenii GK-1 being even more preferred.

[0030] While not limited to Bacillus species, examples include Bacillus coagulans. A specific example of a Bacillus species is Bacillus coagulans strain SANK 70258.

[0031] In addition to the above, the lactic acid bacteria may be bacteria belonging to the genus Akkermansia, Bacteroides, Blautia, Clostridium, Collinsella, Faecalibacterium, Faecalicatena, Lacrimispora, Paeniclostridium, Parabacteroides, or Roseburia.

[0032] The Akkermansia bacteria are not particularly limited, and examples include Akkermansia muciniphila JCM30893.

[0033] The Bacteroides bacteria are not particularly limited, and examples include Bacteroides caccae JCM9498T, Bacteroides fragilis JCM 11019T, Bacteroides fragilis JCM 11017, Bacteroides fragilis JCM 17586, Bacteroides fragilis JCM 17587, Bacteroides ovatus JCM 5824T, Bacteroides thetaiotaomicron ATCC 29148T, Bacteroides thetaiotaomicron ATCC 29741, Bacteroides thetaiotaomicron ATCC 12290, Bacteroides uniformis JCM 5828T, Bacteroides uniformis JCM 13286, Bacteroides uniformis JCM 13287, and Bacteroides uniformis JCM 13288.

[0034] While not particularly limited to the genus Brautia, examples include Brautia acetategigens JCM 34803T, Brautia ammonialitica JCM 34802T, Brautia algi JCM 31394T, Brautia caecimulis JCM 34498T, Brautia coccoides JCM 1395T, Brautia fexis JCM 17205T, Brautia gluceracea JCM 17039T, Brautia hansenii JCM 14655, Brautia hansenii JCM 35484, Brautia hominis JCM 32276T, Brautia hydrogenotropica JCM 31266, Brautia licorice JCM 34225T, and Brautia lutii JCM Examples include 17040T, Brautia obeum JCM 31340, Brautia producta JCM 1471T, Brautia pseudococcoides JCM 35243T, Brautia cinckii JCM 14657T, Brautia vexlerae JCM 31267, and Brautia vexlerae JCM 35486.

[0035] Examples of Clostridium species include, but are not limited to, Clostridium butyricum JCM NT, Clostridium nexile JCM 31500T, and Clostridium cymbiosum JCM 1297T.

[0036] Examples of Cholinella species include, but are not limited to, Cholinella aerofasciens JCM 10188T, Cholinella intestinalis JCM 10643T, Cholinella stercolis JCM 10641T, and Cholinella tanakaei JCM 16071T.

[0037] Examples of bacteria belonging to the genus Faecalibacterium include, but are not limited to, Faecalibacterium hattleyi JCM 39210, Faecalibacterium longum JCM 39208, Faecalibacterium prausnizzi JCM 31915, Faecalibacterium prausnizzi JCM 39207, and Faecalibacterium prausnizzi JCM 39209.

[0038] Examples of bacteria belonging to the genus *Faecalicatena* include *Faecalicatena oroticum* JCM 1429T.

[0039] Examples of Lacrimispora species include, but are not limited to, Lacrimispora celerecrescentis JCM 15734T, Lacrimispora sphenoides JCM 1415T, and Lacrimispora xylanoritica JCM 15735T.

[0040] Examples of Paeniclostridium species include Paeniclostridium sorderii JCM 3814T, although these are not particularly limited.

[0041] Examples of bacteria belonging to the genus Parabacteroides include Parabacteroides meldae JCM 9497T.

[0042] Examples of species belonging to the genus Rosebria include, but are not limited to, Rosebria hominis JCM 17582, Rosebria intestinalis JCM 17583, and Rosebria inulinovorans JCM 17584.

[0043] The lactic acid bacteria relating to this disclosure may be, for example, bacteria of the genus Lactobacillus, in one embodiment Lactobacillus paracasei, in a preferred embodiment Lactobacillus paracasei KW3110 or a mutant thereof, and in a more preferred embodiment Lactobacillus paracasei KW3110. These lactic acid bacteria can suitably achieve improvement of eye and nasal symptoms and prevention of their onset or worsening. While we do not wish to be bound by any theory, it is thought that lactic acid bacteria such as Lactobacillus paracasei KW3110 or its mutants promote the production of cytokines such as interleukin-12 in immune cells such as macrophages in the administered subject, thereby suppressing Th2 cytokines, maintaining a healthy immune balance, improving eye and nasal symptoms, and / or preventing their onset or worsening.

[0044] A mutant strain of Lactobacillus paracasei KW3110 is acceptable as long as it possesses characteristics that can achieve the objectives of this technology (for example, characteristics that improve eye and / or nasal symptoms and / or prevent their onset or worsening). Furthermore, it is preferable that the mutant strain has the same mycological properties as Lactobacillus paracasei KW3110 and possesses an ability to improve eye and / or nasal symptoms and / or prevent their onset or worsening that is equal to or better than that of Lactobacillus paracasei KW3110. Whether a particular mutant strain possesses "an ability to improve eye and / or nasal symptoms and / or prevent their onset or worsening that is equal to or better than that of Lactobacillus paracasei KW3110" can be confirmed, for example, by the evaluation method for symptom improvement or prevention of symptom worsening described later, or by the method described in the examples described later.

[0045] Such mutant strains may be constructed by non-artificially introducing mutations into the above-mentioned Lactobacillus paracasei KW3110. Alternatively, such mutant strains may be constructed by artificially introducing mutations into the above-mentioned Lactobacillus paracasei KW3110, for example by introducing mutations into the bacterium by treatment with a mutagens such as ultraviolet light (UV) or DNA alkylating agents, or by introducing mutations into the strain using gene editing methods such as gene editing represented by CRISPR-Cas9.

[0046] Lactobacillus paracasei KW3110 can be obtained from the Japan Dairy Technology Association and is also deposited as FERM BP-08634 at the Patent Organism Depository Center of the National Institute of Advanced Industrial Science and Technology (AIST) (1-1-1 Higashi, Tsukuba, Ibaraki, Japan 305-8566, Central No. 6) (currently, the Patent Organism Depository Center of the Biotechnology Center of the National Institute of Technology and Evaluation (NITE-IPOD) (Room 120, 2-5-8 Kazusa Kamatari, Kisarazu, Chiba 292-0818, Japan)) as an international depositary authority under the Budapest Convention for the Deposit of Patent Organisms (Deposit Date: February 20, 2004). Furthermore, a mutant strain of Lactobacillus paracasei KW3110 has been deposited with the Patent Organism Depository Center as FERM BP-08635 (deposit date: February 20, 2004).

[0047] As mentioned above, Lactococcus lactis subspecies lactis JCM5805 can be obtained from the Microbial Materials Development Laboratory at the RIKEN BioResource Center. However, in this invention, the same strain of Lactococcus lactis subspecies lactis JCM5805 stored at institutions other than the RIKEN BioResource Center Microbial Materials Development Laboratory can be used. Specifically, the same strain of Lactococcus lactis subspecies lactis JCM5805 can be obtained from the National Institute of Technology and Evaluation (NIITE) Biological Genetics Division (2-5-8 Kazusa-Kamatari, Kisarazu City, Chiba Prefecture), Tokyo University of Agriculture Strain Preservation Room (1-1-1 Sakuragaoka, Setagaya-ku, Tokyo), and the American Type Culture Collection (USA), among others. Lactococcus lactis subspecies lactis JCM5805 is deposited in the American type culture collection as Lactococcus lactis subspecies lactis ATCC9936 and Lactococcus lactis subspecies lactis ATCC19435.

[0048] The lactic acid bacteria relating to this disclosure may be live or dead, and in one embodiment, may include dead bacteria, or may be dead bacteria only. If the lactic acid bacteria relating to this disclosure are dead bacteria, the lactic acid bacteria are not particularly limited, but can be produced by, for example, killing live bacteria by heat treatment, pressurization treatment, high-pressure steam treatment, electromagnetic wave treatment, electron beam treatment, radiation treatment, ultraviolet treatment, alcohol treatment, electrolyzed water treatment, drug treatment, or chemical treatment, and then drying them as necessary by freeze-drying, spray drying, drum drying, hot air drying, or vacuum drying. For example, the lactic acid bacteria relating to one embodiment may be heat-treated bacteria.

[0049] <Eye and nose symptoms> Symptoms of the eyes and / or nose (also referred to as "ophthalmosal symptoms") are symptoms of the eyes, symptoms of the nose, or symptoms of both the eyes and nose. Ophthalmosal symptoms are abnormal conditions occurring in the eyes and nose. Ophthalmosal symptoms may be subjective and / or objective symptoms, and objective symptoms may be symptoms observed during a medical examination or symptoms observed during examination using medical equipment. Ophthalmosal symptoms may be functional abnormalities and / or morphological abnormalities, each of which may be symptoms observed during a medical examination or symptoms observed during examination using medical equipment. In these cases, the physician performing the examination may be, for example, an otolaryngologist or an ophthalmologist, and in a preferred embodiment, an otolaryngologist. Furthermore, in these cases, the diagnosis made by the physician may be a diagnosis made in accordance with the diagnostic guidelines for ophthalmosal symptoms, for example, a diagnosis made in accordance with the 2020 edition of the Diagnostic Guidelines for Nasal Allergies (9th revised edition, Japanese Society of Otolaryngology, Immunology and Allergy and Infectious Diseases).

[0050] The ophthalmic and nasal symptoms in one embodiment may be ophthalmic and nasal symptoms caused by an allergy, and may also be ophthalmic and nasal symptoms caused by an allergy to an allergen that enters the body through at least one selected from the group consisting of the eyes, nose, and mouth, and include allergic ophthalmorhinitis (including allergic rhinitis and allergic conjunctivitis, etc.). The ophthalmic and nasal symptoms in a preferred embodiment may be ophthalmic and nasal symptoms caused by an allergy to an inhaled allergen. Inhalant allergens refer to allergens that are present in the air and enter the body through respiration. Examples of inhalant allergens include plant allergens, animal allergens, airborne particulate matter, bacteria, fungi, or house dust (such as pet or human hair, dander, fungi, bacteria, mites, sand, fibrous materials, or mixtures thereof). Examples of plant allergens include pollen, and those caused by pollen are also called pollen allergens. Pollen as an allergen is not particularly limited, but examples include pollen from cypress family plants (Cupressaceae), grass family plants (Poaceae), aster family plants (Asteraceae), betulaceae, cannabaceae, or elm family plants. In one embodiment, the pollen as an allergen may be pollen from cypress family plants. In a preferred embodiment, the pollen as an allergen may be pollen from plants of the genus Cryptomeria and / or Chamaecyparis. In a more preferred embodiment, the pollen as an allergen may be pollen from Japanese cedar (Cryptomeria japonica) and / or Japanese cypress (Chamaecyparis obtusa). Examples of cypress family plants whose pollen is an allergen include Japanese cedar (Cryptomeria japonica) and Japanese cypress (Chamaecyparis obtusa). Examples of grass family plants whose pollen is an allergen include orchard grass (Timbergrass), timothy grass (Orchard grass), and ryegrass (Ramaria veitchii). Examples of daisy family plants whose pollen is an allergen include ragweed (Asteraceae) and mugwort (Artemisia princeps). Examples of birch family plants whose pollen is an allergen include birch (Betula genus) and alder (Alnus japonica). Examples of hemp family plants whose pollen is an allergen include Japanese hop (Humulus humilis). Examples of elm family plants whose pollen is an allergen include zelkova (Zelkova serrata). Symptoms caused by allergies to pollen are sometimes called hay fever. Examples of animal allergens include the carcasses or feces of mites such as house dust mites, flour mites, dust mites, or predatory mites, or the skin (dander) or hair of dogs or cats. Suspended particulate matter (SPM) refers to solid and liquid particles suspended in the atmosphere, classified by particle size (also called atmospheric aerosols), and includes yellow dust. Environmental standards define suspended particulate matter as PM10 (particles 10 μm or less) or PM2.5 (fine particulate matter 2.5 μm or less). Suspended particulate matter may contain carbon components, nitrates, sulfates, and ammonium salts, as well as inorganic elements such as silicon, sodium, and aluminum. Furthermore, suspended particulate matter may also contain materials that serve as carriers for radioactive materials such as radioactive cesium. Here, "yellow dust" generally refers to sand and dust carried by wind from the Yellow River basin and deserts, with particle size around 4 μm. Other allergens include, for example, fungi, bacteria (excluding lactic acid bacteria that improve eye and nasal symptoms and / or prevent their onset or worsening), dust, fibrous materials, suspended particulate matter, and asbestos.

[0051] Of the allergens mentioned above, some inhaled allergens, such as pollen, are naturally occurring allergens, and these are generally more abundant outdoors and outside (including outdoors) than indoors. Thus, the symptoms in the eye and nose symptoms of one aspect may be symptoms of outdoor and / or outdoor living, symptoms of outdoor living, or symptoms of outdoor living. Symptoms of outdoor and / or outdoor living refer to symptoms that occur as a result of the subject staying outdoors and / or outside, and include inconveniences that occur as a result of staying outdoors and / or outside (inconveniences to outdoor and / or outdoor living). Note that outdoor and / or outdoor living includes situations in which activities such as sports and picnics are performed. For example, the eye and nose symptoms of one aspect may be eye and nose symptoms caused by an allergy to an outdoor allergen or an outdoor allergen (including outdoor allergens). The inventors demonstrated that, regarding the items related to outdoor activities (questions 6-7) in the "QOL questionnaire" of the Japanese Standard QOL Questionnaire for Allergic Rhinitis (JRQLQ No. 1), the group administered lactic acid bacteria or a composition containing them showed significantly better results compared to the placebo group.

[0052] In a more preferred embodiment, the ophthalmic and nasal symptoms may be those caused by an allergy to pollen. In a more preferred embodiment, the ophthalmic and nasal symptoms may be those caused by hay fever.

[0053] The nasal and eye symptoms in one aspect may be any of the nasal and eye symptoms listed in the "Severity of nasal and eye symptoms" section of the Japanese Standard Quality of Life Questionnaire for Allergic Rhinitis (JRQLQ No. 1). In other words, the nasal and eye symptoms in one aspect may be at least one selected from the group consisting of runny nose, sneezing, nasal congestion, nasal itchiness, eye itchiness, and watery eyes.

[0054] Furthermore, the ophthalmic and nasal symptoms in one embodiment may be at least one selected from the group consisting of sneezing fits, runny nose, and nasal congestion. These are designated as examination items in the 2020 Guidelines for the Diagnosis of Nasal Allergies. The ophthalmic and nasal symptoms in a more preferred embodiment may be sneezing fits and / or runny nose. The inventors have demonstrated that, based on physician-diagnosed severity classifications of sneezing fits and / or runny nose, the group administered lactic acid bacteria or a composition containing them showed significantly better results compared to the placebo group.

[0055] Furthermore, the ophthalmic and nasal symptoms in one embodiment may be at least one selected from the group consisting of swelling of the inferior turbinate mucosa, color of the inferior turbinate mucosa, amount of aqueous secretion, and nasal discharge. These may be evaluated, for example, as local findings by an otolaryngologist based on intranasal evaluation using rhinoscopy. A preferred ophthalmic and nasal symptom in one embodiment may be swelling of the inferior turbinate mucosa. The inventors have demonstrated that, based on intranasal evaluation using rhinoscopy, the local finding of swelling of the inferior turbinate mucosa was significantly better in the group administered lactic acid bacteria or a composition containing them compared to the placebo group.

[0056] Furthermore, the ocular and nasal symptoms in one embodiment may be at least one selected from the group consisting of sneezing, runny nose, nasal congestion, itchy eyes, and watery eyes (epiphora). These are the symptoms listed as subjective symptoms in the 2020 Guidelines for the Diagnosis of Nasal Allergies. The preferred ocular and nasal symptom in one embodiment may be runny nose. Based on subject diaries, the inventors have demonstrated that in terms of runny nose, the group administered lactic acid bacteria or a composition containing them showed significantly better results compared to the placebo group.

[0057] As described above, the ophthalmic and nasal symptoms in one embodiment may be at least one selected from the group consisting of runny nose, nasal congestion, nasal itchiness, eye itchiness, watery eyes (tears, drooling), sneezing, sneezing fits, rhinorrhea, nasal congestion, severity of nasal congestion, swelling of the inferior turbinate mucosa, color of the inferior turbinate mucosa, amount of aqueous secretion, and nasal discharge. Furthermore, the ophthalmic and nasal symptoms in a preferred embodiment may be at least one selected from the group consisting of sneezing fits, rhinorrhea, swelling of the inferior turbinate mucosa, and nasal discharge.

[0058] <Improvement of symptoms> In this disclosure, improvement of symptoms may mean at least a temporary reduction or disappearance of the symptoms (remission), and / or complete disappearance of the symptoms (cure). Remission may be, for example, complete remission in which all symptoms are relieved, or partial remission in which some symptoms are relieved.

[0059] Furthermore, since eye and nasal symptoms generally directly affect quality of life (QOL), improvement in these symptoms alleviates the resulting discomfort. In other words, improvement in eye and nasal symptoms in one aspect may mean a reduction in the decline of quality of life (QOL) and / or alleviation of discomfort caused by these symptoms. Alleviation of discomfort may include, for example, suppression or complete elimination of discomfort.

[0060] In this disclosure, improvement in symptoms may be evaluated based on, for example, a lower severity of symptoms in the group administered lactic acid bacteria or a composition containing them compared to the placebo group. More specifically, for example, if the severity of symptoms is scored, and the score of the group administered lactic acid bacteria or a composition containing them is significantly lower than the score of the placebo group, or shows a tendency toward lower symptoms, then it may be determined that the symptoms have improved. Alternatively, for example, if the severity of symptoms is scored, and the score of the group administered lactic acid bacteria or a composition containing them changes over time in a direction that significantly indicates a lower severity of symptoms, or shows a tendency toward lower symptoms, then it may be determined that the symptoms have improved.

[0061] <Prevention of symptom onset or worsening> In this disclosure, prevention of the onset or worsening of symptoms is also referred to as suppression of the onset or worsening of symptoms, and includes suppression of the occurrence of the symptoms themselves, the degree of worsening of symptoms that have occurred, and / or the rate at which they worsen.

[0062] In this disclosure, prevention of symptom onset may be evaluated, for example, based on a reduction in the frequency of onset and / or a delay in the timing of onset in a group administered lactic acid bacteria or a composition containing the same, compared to a placebo group. In this disclosure, prevention of symptom exacerbation may be evaluated, for example, based on a suppression of the degree and / or rate of symptom worsening in a group administered lactic acid bacteria or a composition containing the same, compared to a placebo group. Using examples where symptoms are scored as most severe, severe, moderate, mild, and asymptomatic, we will explain in detail how to prevent the onset and worsening of symptoms. Regarding the prevention of symptom onset, for example, if the severity of symptoms is scored, and the score at a certain point in time for the group administered lactic acid bacteria or a composition containing them corresponds to asymptomatic, while the score for the placebo group at the same point in time corresponds to very severe, severe, moderate, or mild, it may be judged that the onset of symptoms was prevented by administration. Alternatively, for example, if the severity of symptoms is scored, and the score at a certain point in time for the group administered lactic acid bacteria or a composition containing them is significantly lower than the score for the placebo group at the same point in time, indicating a symptomatic level that can be classified as asymptomatic, it may be judged that the onset of symptoms was prevented by administration. Furthermore, for example, if the timing of the transition from asymptomatic to very severe, severe, moderate, or mild in the score is later in the group administered lactic acid bacteria or a composition containing them than in the placebo group, it may be judged that the onset of symptoms was prevented by administration. Furthermore, regarding the prevention of symptom exacerbation, for example, if the severity of symptoms is scored, and the score at a certain point in time of the group administered lactic acid bacteria or a composition containing them is significantly lower in severity of symptoms than the score of the placebo group at the same point in time, or if the score indicates a tendency toward lower severity of symptoms, then it may be judged that the exacerbation of symptoms was prevented by administration. Also, for example, if the amount or rate of change in the score over time in the group administered lactic acid bacteria or a composition containing them is significantly lower in severity of symptoms than the amount or rate of change in the score over time in the placebo group, or if the score indicates a tendency toward lower severity of symptoms, then it may be judged that the exacerbation of symptoms was prevented by administration.

[0063] <Composition> A first embodiment of this disclosure relates to a composition containing lactic acid bacteria. The composition of this embodiment may be a composition for improving symptoms of the eyes and / or nose and / or for preventing their onset or worsening. In this case, this embodiment can also be said to be an agent for improving symptoms of the eyes and / or nose and / or for preventing their onset or worsening, or an agent for improving symptoms of the eyes and / or nose and / or for preventing their onset or worsening.

[0064] The composition according to this embodiment may be, for example, a food composition, a pharmaceutical composition, or a quasi-drug, and in one preferred embodiment it may be a food composition or a pharmaceutical composition, and in one more preferred embodiment it may be a food composition.

[0065] In the composition according to this embodiment, the lactic acid bacteria content is not particularly limited and should be an amount that satisfies an effective amount for improving eye and nasal symptoms and / or preventing their onset or worsening. Therefore, the lactic acid bacteria content may vary depending on the form of the composition according to this embodiment. For example, with respect to the total dry weight of the composition according to this embodiment, the dry weight of lactic acid bacteria may be 0.0001% by mass or more, 0.001% by mass or more, 0.005% by mass or more, 0.01% by mass or more, 0.02% by mass or more, 0.05% by mass or more, 0.10% by mass or more, 0.30% by mass or more, 1.0% by mass or more, 1.5% by mass or more, 2.0% by mass or more, 2.5% by mass or more, 3.0% by mass or more, 5.0% by mass or more, 7. The lower and upper limits may be 0% or more by mass, 10.0% or more by mass, 80.0% or more by mass, 90.0% or more by mass, 95.0% or more by mass, 99.0% or more by mass, or 100% by mass, and may also be 100% or less by mass, 95% or less by mass, 90% or less by mass, 80% or less by mass, 70% or less by mass, 60% or less by mass, 50% or less by mass, 30% or less by mass, 25% or less by mass, 20% or less by mass, 15% or less by mass, or 10% or less by mass. These lower and upper limits can be combined in any way and are not particularly limited. For example, with respect to the total dry weight of the composition according to this embodiment, the dry weight of lactic acid bacteria is 0.0001% to 100% by mass, 0.0001% to 95% by mass, 0.0001% to 90% by mass, 0.0001% to 80% by mass, 0.0001% to 70% by mass, 0.0001% to 60% by mass, 0.0001% to 50% by mass, 0.0001% to 30% by mass, 0.0001% to 25% by mass, 0.0001% to 20% by mass, and 0.0001% to 15% by mass. % or less, 0.0001 mass% or more and 10 mass% or less, 0.001 mass% or more and 100 mass% or less, 0.001 mass% or more and 95 mass% or less, 0.001 mass% or more and 90 mass% or less, 0.001 mass% or more and 80 mass% or less, 0.001 mass% or more and 70 mass% or less, 0.001 mass% % to 60 mass%, 0.001 mass% to 50 mass%, 0.001 mass% to 30 mass%, 0.001 mass% to 25 mass%, 0.001 mass% to 20 mass%, 0.001 mass% to 15 mass%, 0.001 mass% to 10 mass%, 0.0.005% to 100% mass, 0.005% to 95% mass, 0.005% to 90% mass, 0.005% to 80% mass, 0.005% to 70% mass, 0.005% to 60% mass, 0.005% to 50% mass, 0.005% to 30% mass, 0.005% to 25% mass, 0.005% to 20% mass, 0.005% to 15% mass, 0.005% to 10% mass, 0.01% to 100% mass, 0.01% to 95% mass Below %, 0.01% to 90% of mass, 0.01% to 80% of mass, 0.01% to 70% of mass, 0.01% to 60% of mass, 0.01% to 50% of mass, 0.01% to 30% of mass, 0.01% to 25% of mass, 0.01% to 20% of mass, 0.01% to 15% of mass, 0.01% to 10% of mass, 0.02% to 100% of mass, 0.02% to 95% of mass, 0.02% to 90% of mass, 0.02% to 80% of mass, 0.02 Quality percentages above 70% and below 70%, 0.02% and above 60% and below 60%, 0.02% and above 50% and below 50%, 0.02% and above 30% and below 30%, 0.02% and above 25% and below 20%, 0.02% and above 15% and below 15%, 0.02% and above 10% and below 10%, 0.05% and above 100% and below 100%, 0.05% and above 95% and below 95%, 0.05% and above 90% and below 90%, 0.05% and above 80% and below 80%, 0.05% and above 70% and below 70%, 0.05% and above 60% and below 60%, 0.05% and above 50% and below 60%. Below 100% of mass, 0.05% to 30% of mass, 0.05% to 25% of mass, 0.05% to 20% of mass, 0.05% to 15% of mass, 0.05% to 10% of mass, 0.10% to 100% of mass, 0.10% to 95% of mass, 0.10% to 90% of mass, 0.10% to 80% of mass, 0.10% to 70% of mass, 0.10% to 60% of mass, 0.10% to 50% of mass, 0.10% to 30% of mass, 0.10% to 25% of mass, 0.10% to 20% by mass, 0.10% to 15% by mass, 0.10% to 10% by mass, 0.30% to 100% by mass, 0.30% to 95% by mass, 0.30% to 90% by mass, 0.30% to 80% by mass, 0.30% to 70% by mass, 0.30% to 60% by mass, 0.30% to 50% by mass, 0.30% to 30% by mass, 0.30% to 25% by mass, 0.30% to 20% by mass, 0.30% to 15% by mass, 0.30% to 10% by mass Less than 1% of mass, 1.0% to 100% of mass, 1.0% to 95% of mass, 1.0% to 90% of mass, 1.0% to 80% of mass, 1.0% to 70% of mass, 1.0% to 60% of mass, 1.0% to 50% of mass, 1.0% to 30% of mass, 1.0% to 25% of mass, 1.0% to 20% of mass, 1.0% to 15% of mass, 1.0% to 10% of mass, 1.5% to 100% of mass, 1.5% to 95% of mass, 1.5% to 90% of mass, 1. 5% to 80% mass, 1.5% to 70% mass, 1.5% to 60% mass, 1.5% to 50% mass, 1.5% to 30% mass, 1.5% to 25% mass, 1.5% to 20% mass, 1.5% to 15% mass, 1.5% to 10% mass, 2.0% to 100% mass, 2.0% to 95% mass, 2.0% to 90% mass, 2.0% to 80% mass, 2.0% to 70% mass, 2.0% to 60% mass, 2.0% to 50% mass. Below 2.0% of mass, 2.0% to 30% of mass, 2.0% to 25% of mass, 2.0% to 20% of mass, 2.0% to 15% of mass, 2.0% to 10% of mass, 2.5% to 100% of mass, 2.5% to 95% of mass, 2.5% to 90% of mass, 2.5% to 80% of mass, 2.5% to 70% of mass, 2.5% to 60% of mass, 2.5% to 50% of mass, 2.5% to 30% of mass, 2.5% to 25% of mass, 2.5% to 20% of mass, 2.5% by mass or more and 15% by mass or less, 2.5% by mass or more and 10% by mass or less, 3.0% by mass or more and 100% by mass or less, 3.0% by mass or more and 95% by mass or less, 3.0% by mass or more and 90% by mass or less, 3.0% by mass or more and 80% by mass or less, 3.0% by mass or more and 70% by mass or less, 3.0% by mass or more and 60% by mass or less, 3.0% by mass or more and 50% by mass or less, 3.0% by mass or more and 30% by mass or less, 3.0% by mass or more and 25% by mass or less, 3.0% by mass or more and 20% by mass or less, 3.0% by mass or more and 15% by mass or less, 3.0% by mass or more and 10% by mass or less, 5.0% by mass or more and 100% by mass or less, 5.0% by mass or more and 95% by mass or less, 5.0% by mass or more and 90% by mass or less, 5.0% by mass or more and 80% by mass or less, 5.0% by mass or more and 70% by mass or less, 5.0% by mass or more and 60% by mass or less, 5.0% by mass or more and 50% by mass or less, 5.0% by mass or more and 30% by mass or less, 5.0% by mass or more and 25% by mass or less, 5.0% by mass or more and 20% by mass or less, 5.0% by mass or more and 15% by mass or less, 5.0% by mass or more and 10% by mass or less, 7.0% by mass or more and 100% by mass or less, 7.0% by mass or more and 95% by mass or less, 7.0% by mass or more and 90% by mass or less, 7.0% by mass or more and 80% by mass or less, 7.0% by mass or more and 70% by mass or less, 7.0% by mass or more and 60% by mass or less, 7.0% by mass or more and 50% by mass or less, 7.0% by mass or more and 30% by mass or less, 7.0% by mass or more and 25% by mass or less, 7.0% by mass or more and 20% by mass or less, 7.0% by mass or more and 15% by mass or less, 7.0% by mass or more and 10% by mass or less, 10.0% by mass or more and 100% by mass or less, 10.0% by mass or more and 95% by mass or less, 10.0% by mass or more and 90% by mass or less, 10.0% by mass or more and 80% by mass or less, 10.0% by mass or more and 70% by mass or less, 10.0% by mass or more and 60% by mass or less, 10.0% by mass or more and 50% by mass or less, 10.0% by mass or more and 30% by mass or less, 10.0% by mass or more and 25% by mass or less, 10.0% by mass or more and 20% by mass or less, 10.0% by mass or more and 15% by mass or less, 80.0% by mass or more and 100% by mass or less, 80.0% by mass or more and 95% by mass or less, 80.0% by mass or more and 90% by mass or less, 90.0% by mass or more and 100% by mass or less, 90.0% by mass or more and 95% by mass or less or 95.0% by mass or more and 100% by mass or less, and may preferably be 3% by mass to 15% by mass..

[0066] When the composition according to this embodiment is in liquid form, the number of lactic acid bacteria contained in the composition according to this embodiment is 1.0 × 10 3 Cells / mL or more, 1.0×10 4 Cells / mL or more, 1.0×10 5 Cells / mL or more, 1.0×10 6 Cells / mL or more, 1.0×10 7 Cells / mL or more or 4.0 × 10 7 The concentration may be greater than or equal to 1.0 × 10⁻¹⁰ cells / mL. 11 Cells / mL or less, 1.0×10 10 Cells / mL or less, 3.0×10 9 Cells / mL or less or 1.0 × 10 9 The number of cells / mL or less may also be less. These lower and upper limits can be combined in any way and are not particularly limited. For example, the number of lactic acid bacteria contained in the composition according to this embodiment is 1.0 × 10⁶ 3 cells / mL or more 1.0×10 11 Cells / mL or less, 1.0×10 3 cells / mL or more 1.0×10 10 Cells / mL or less, 1.0×10 3 cells / mL or more 3.0×10 9 Cells / mL or less, 1.0×10 3 cells / mL or more 1.0×10 9 Cells / mL or less, 1.0×10 4 cells / mL or more 1.0×10 11 Cells / mL or less, 1.0×10 4 cells / mL or more 1.0×10 10 Cells / mL or less, 1.0×10 4 cells / mL or more 3.0×10 9 Cells / mL or less, 1.0×10 4 cells / mL or more 1.0×10 9 Cells / mL or less, 1.0×10 5 cells / mL or more 1.0×10 11 Cells / mL or less, 1.0×10 5 cells / mL or more 1.0×10 10 Cells / mL or less, 1.0×10 5 cells / mL or more 3.0×10 9 Cells / mL or less, 1.0×10 5 1.0×10 or more cells / mL 9 1.0×10 or less cells / mL 6 1.0×10 or more cells / mL 11 1.0×10 or less cells / mL 6 1.0×10 or more cells / mL 10 1.0×10 or less cells / mL 6 3.0×10 or more cells / mL 9 1.0×10 or less cells / mL 6 1.0×10 or more cells / mL 9 1.0×10 or less cells / mL 7 1.0×10 or more cells / mL 11 1.0×10 or less cells / mL 7 1.0×10 or more cells / mL 10 1.0×10 or less cells / mL 7 3.0×10 or more cells / mL 9 1.0×10 or less cells / mL 7 1.0×10 or more cells / mL 9 4.0×10 or less cells / mL 7 1.0×10 or more cells / mL 11 4.0×10 or less cells / mL 7 1.0×10 or more cells / mL 10 4.0×10 or less cells / mL 7 3.0×10 or more cells / mL 9 4.0×10 or less cells / mL 7 1.0×10 or more cells / mL 9 It may be 1.0×10 or less cells / mL. In this case, the daily dosage of the liquid composition may be 10 mL to 1,000 mL, 10 mL to 800 mL, 10 mL to 500 mL, 10 mL to 250 mL, 30 mL to 1,000 mL, 30 mL to 800 mL, 30 mL to 500 mL, 30 mL to 250 mL, 50 mL to 1,000 mL, 50 mL to 800 mL, 50 to 500 mL, 50 mL to 250 mL, 100 mL to 1,000 mL, 100 mL to 800 mL, 100 to 500 mL or 100 to 250 mL.

[0067] In the composition according to this embodiment, the number of lactic acid bacteria per unit package is 1.0×10 5 or more, 3.0×10 5 or more than 1.0×10 6 or more than 3.0×10 6 or more than 1.0×10 7 or more than 3.0×10 7 or more than 1.0×10 8 or more than 3.0×10 8 or more than 5.0×10 8 or more than 1.0×10 9 or more than 5.0×10 9 or more than 1.0×10 10 or more than 5.0×10 10 or more than 8.0×10 10 or more than 1.0×10 14 or less than 1.0×10 13 or less than 1.0×10 12 or less than 3.0×10 11 or less than 2.0×10 11 or less than. These upper and lower limits can be arbitrarily combined and are not particularly limited. For example, in the composition according to this embodiment, the number of lactic acid bacteria per unit package is 1.0×10 5 or more and 1.0×10 14 or less, 1.0×10 5 or more and 1.0×10 13 or less, 1.0×10 5 or more and 1.0×10 12 or less, 1.0×10 5 or more and 3.0×10 11 or less, 1.0×10 5 or more and 2.0×10 11 or less, 3.0×10 5 or more and 1.0×10 14 or less, 3.0×10 5 or more and 1.0×10 13 or less, 3.0×10 5 or more and 1.0×10 12 or less, 3.0×10 5 or more and 3.0×10 11 or less, 3.0×10 5 or more and 2.0×10<​​​​​​More than 1.0 × 10 13 Less than 1.0 × 10 6 More than 1.0 × 10 12 Less than 1.0 × 10 6 More than 3.0 × 10 11 Less than 1.0 × 10 6 More than 2.0 × 10 11 Less than 3.0 × 10 6 More than 1.0 × 10 14 Less than 3.0 × 10 6 More than 1.0 × 10 13 Less than 3.0 × 10 6 More than 1.0 × 10 12 Less than 3.0 × 10 6 More than 3.0 × 10 11 Less than 3.0 × 10 6 More than 2.0 × 10 11 Less than 1.0 × 10 7 More than 1.0 × 10 14 Less than 1.0 × 10 7 More than 1.0 × 10 13 Less than 1.0 × 10 7 More than 1.0 × 10 12 Less than 1.0 × 10 7 More than 3.0 × 10 11 Less than 1.0 × 10 7 More than 2.0 × 10 11 Less than 3.0 × 10 7 More than 1.0 × 10 14 Less than 3.0 × 10 7 More than 1.0 × 10 13 Less than 3.0 × 10 7 More than 1.0 × 10 12 Less than 3.0 × 10 7 More than 3.0 × 10 11 Less than 3.0 × 10 7 More than 2.0 × 10 11 Less than 1.0 × 10 8 More than 1.0 × 10 14 Less than 1.0 × 10 8 More than 1.0 × 10 13 Less than 1.0 × 10 8 More than 1.0 × 10 12 Less than 1.0 × 10 8 More than 3.0 × 10 11 Less than 1.0 × 10 8 More than 2.0 × 10 11 Less than 3.0 × 10 8 More than 1.0 × 10 14 Less than 3.0 × 10 8 More than 1.0 × 10 13 Less than 3.0 × 10 8 More than 1.0 × 10 12 Less than 3.0 × 10 8 More than 3.0 × 10 11 Less than 3.0 × 10 8 More than 2.0 × 10 11 Less than 5.0 × 10 8 More than 1.0 × 10 14 Less than 5.0 × 10 8 More than 1.0 × 10 13 Less than 5.0 × 10 8 More than 1.0 × 10 12 Less than 5.0 × 10 8 More than 3.0 × 10 11 Less than 5.0 × 10 8 More than 2.0 × 10 11 Less than 1.0 × 10 9 More than 1.0 × 10 14 Less than 1.0 × 10 9 More than 1.0 × 10 13 Less than 1.0 × 10 9 More than 1.0 × 10 12 Less than 1.0 × 10 9 More than 3.0 × 10 11 Less than 1.0 × 10 9 More than 2.0 × 10 11 Less than 5.0 × 10 9 More than 1.0 × 10 14 Less than 5.0 × 10 9 More than 1.0 × 10 13 Less than 5.0 × 10 9 More than 1.0 × 10 12 Less than 5.0 × 10 9 More than 3.0 × 10 11 Less than 5.0 × 10 9 More than 2.0 × 10 11 Less than 1.0 × 10 10 More than 1.0 × 10 14 pcs or less, 1.0×10 10 pcs or more 1.0×10 13 pcs or less, 1.0×10 10 pcs or more 1.0×10 12 pcs or less, 1.0×10 10 pcs or more 3.0×10 11 pcs or less, 1.0×10 10 pcs or more 2.0×10 11 Less than or equal to 5.0×10 10 pcs or more 1.0×10 14 Less than or equal to 5.0×10 10 pcs or more 1.0×10 13 Less than or equal to 5.0×10 10 pcs or more 1.0×10 12 Less than or equal to 5.0×10 10 pcs or more 3.0×10 11 Less than or equal to 5.0×10 10 pcs or more 2.0×10 11 pcs or less, 8.0×10 10 pcs or more 1.0×10 14 pcs or less, 8.0×10 10 pcs or more 1.0×10 13 pcs or less, 8.0×10 10 pcs or more 1.0×10 12 pcs or less, 8.0×10 10 pcs or more 3.0×10 11 1 or fewer, or 8.0 × 10 10 pcs or more 2.0×10 11 It may be less than or equal to 5.0 × 10 units. In the composition according to this embodiment, the number of lactic acid bacteria per unit package is, for example, 5.0 × 10 units. 10 pcs or more 3.0×10 11 1 or fewer, or 8.0 × 10 10 pcs or more 2.0×10 11 If the number is less than or equal to one unit package, administering one unit package per day can effectively improve eye and nasal symptoms and / or prevent their onset or worsening.

[0068] The administration method of the composition according to this embodiment is not particularly limited, but oral administration is preferred, and oral ingestion is more preferred, from the viewpoint of reducing the burden on the recipient. In this disclosure, oral ingestion means that the recipient actively takes in the composition orally. When used for oral administration, the lactic acid bacteria and / or the composition containing them may have high resistance to gastric juice and intestinal juice, etc., and is not particularly limited, but for example, it is preferable to have strong acid resistance.

[0069] The composition according to this embodiment may be administered to humans and / or non-human mammals, and in one embodiment may be administered to humans. In other words, the target to which the composition according to this embodiment is administered may be humans and / or non-human mammals, and may be humans.

[0070] The composition according to this embodiment can be administered to subjects who require improvement of eye and nasal symptoms and / or prevention of their onset or worsening. Subjects to whom the composition according to this embodiment is administered may be, for example, subjects who have eye and nasal symptoms and / or allergies, and / or subjects who have the possibility and / or risk of having them, and may be subjects who have eye and nasal symptoms and / or allergies. Subjects who have eye and nasal symptoms may preferably be subjects who have mild to moderate eye and nasal symptoms. Subjects who have allergies may preferably be subjects with allergic ophthalmorhinoitis or subjects suffering from hay fever. More preferably, subjects to whom the composition according to this embodiment is administered may be subjects with mild to moderate allergic ophthalmorhinoitis. The severity classification of allergic rhinitis symptoms, such as mild and moderate, is not particularly limited, but can be done, for example, by the method described in the examples. Specifically, in accordance with the 2020 Guidelines for the Diagnosis of Rhinitis, an otolaryngologist will evaluate the combination of sneezing or runny nose and the severity of nasal congestion on a five-point scale: "most severe," "severe," "moderate," "mild," and "asymptomatic." The scores will then be calculated and tallied as follows: "Most severe: 4 points," "Severe: 3 points," "Moderate: 2 points," "Mild: 1 point," and "Asymptomatic: 0 points."

[0071] The daily dose of the composition according to this embodiment can be determined depending on the recipient's sex, age and weight, symptoms, administration time, dosage form, route of administration, and the materials or drugs to be combined. The daily dose of the composition according to this embodiment (for example, the daily dose for an adult) is not particularly limited, but for example, based on the number of lactic acid bacteria, it may be 1.0 × 10⁻⁶. 5 pcs or more, 3.0×10 5 pcs or more, 1.0×10 6 pcs or more, 3.0×10 6 pcs or more, 1.0×10 7 pcs or more, 3.0×10 7 pcs or more, 1.0×10 8 pcs or more, 3.0×10 8 pcs or more, 5.0×10 8 pcs or more, 1.0×10 9 pcs or more, 5.0×10 9 pcs or more, 1.0×10 10 pcs or more, 5.0×10 10 One or more or 8.0 × 10 10 There may be more than 1.0 × 10 14 pcs or less, 1.0×10 13 pcs or less, 1.0×10 12 pcs or less, 3.0×10 11 1 or less or 2.0 × 10 11 The number may be less than or equal to 10. Furthermore, these upper and lower limits can be combined arbitrarily and are not particularly limited. For example, the daily dose of the composition according to this embodiment (for example, the daily dose for an adult) is 1.0 × 10 based on the number of lactic acid bacteria. 5 pcs or more 1.0×10 14 pcs or less, 1.0×10 5 pcs or more 1.0×10 13 pcs or less, 1.0×10 5 pcs or more 1.0×10 12 pcs or less, 1.0×10 5 pcs or more 3.0×10 11 pcs or less, 1.0×10 5 pcs or more 2.0×10 11 pcs or less, 3.0×10 5 pcs or more 1.0×10 14 pcs or less, 3.0×10 5 More than 1.0 × 10 13 Less than 3.0 × 10 5 More than 1.0 × 10 12 Less than 3.0 × 10 5 More than 3.0 × 10 11 Less than 3.0 × 10 5 More than 2.0 × 10 11 Less than 1.0 × 10 6 More than 1.0 × 10 14 Less than 1.0 × 10 6 More than 1.0 × 10 13 Less than 1.0 × 10 6 More than 1.0 × 10 12 Less than 1.0 × 10 6 More than 3.0 × 10 11 Less than 1.0 × 10 6 More than 2.0 × 10 11 Less than 3.0 × 10 6 More than 1.0 × 10 14 Less than 3.0 × 10 6 More than 1.0 × 10 13 Less than 3.0 × 10 6 More than 1.0 × 10 12 Less than 3.0 × 10 6 More than 3.0 × 10 11 Less than 3.0 × 10 6 More than 2.0 × 10 11 Less than 1.0 × 10 7 More than 1.0 × 10 14 Less than 1.0 × 10 7 More than 1.0 × 10 13 Less than 1.0 × 10 7 More than 1.0 × 10 12 Less than 1.0 × 10 7 More than 3.0 × 10 11 Less than 1.0 × 10 7 More than 2.0 × 10 11 Less than 3.0 × 10 7 More than 1.0 × 10 14 Less than 3.0 × 10 7 More than 1.0 × 10 13 Less than 3.0 × 10 7 More than 1.0 × 10 12 Less than 3.0 × 10 7 More than 3.0 × 10 11 Less than 3.0 × 10 7 More than 2.0 × 10 11 Less than 1.0 × 10 8 More than 1.0 × 10 14 Less than 1.0 × 10 8 More than 1.0 × 10 13 Less than 1.0 × 10 8 More than 1.0 × 10 12 Less than 1.0 × 10 8 More than 3.0 × 10 11 Less than 1.0 × 10 8 More than 2.0 × 10 11 Less than 3.0 × 10 8 More than 1.0 × 10 14 Less than 3.0 × 10 8 More than 1.0 × 10 13 Less than 3.0 × 10 8 More than 1.0 × 10 12 Less than 3.0 × 10 8 More than 3.0 × 10 11 Less than 3.0 × 10 8 More than 2.0 × 10 11 Less than 5.0 × 10 8 More than 1.0 × 10 14 Less than 5.0 × 10 8 More than 1.0 × 10 13 Less than 5.0 × 10 8 More than 1.0 × 10 12 Less than 5.0 × 10 8 More than 3.0 × 10 11 Less than 5.0 × 10 8 More than 2.0 × 10 11 Less than 1.0 × 10 9 More than 1.0 × 10 14 Less than 1.0 × 10 9 More than 1.0 × 10 13 Less than 1.0 × 10 9 More than 1.0 × 10 12 Less than 1.0 × 10 9 More than 3.0 × 10 11 Less than 1.0 × 10 9 More than 2.0 × 10 11 Less than 5.0 × 10 9 More than 1.0 × 10 14 Less than or equal to 5.0×10 9 pcs or more 1.0×10 13 Less than or equal to 5.0×10 9 pcs or more 1.0×10 12 Less than or equal to 5.0×10 9 pcs or more 3.0×10 11 Less than or equal to 5.0×10 9 pcs or more 2.0×10 11 pcs or less, 1.0×10 10 pcs or more 1.0×10 14 pcs or less, 1.0×10 10 pcs or more 1.0×10 13 pcs or less, 1.0×10 10 pcs or more 1.0×10 12 pcs or less, 1.0×10 10 pcs or more 3.0×10 11 pcs or less, 1.0×10 10 pcs or more 2.0×10 11 Less than or equal to 5.0×10 10 pcs or more 1.0×10 14 Less than or equal to 5.0×10 10 pcs or more 1.0×10 13 Less than or equal to 5.0×10 10 pcs or more 1.0×10 12 Less than or equal to 5.0×10 10 pcs or more 3.0×10 11 Less than or equal to 5.0×10 10 pcs or more 2.0×10 11 pcs or less, 8.0×10 10 pcs or more 1.0×10 14 pcs or less, 8.0×10 10 pcs or more 1.0×10 13 pcs or less, 8.0×10 10 pcs or more 1.0×10 12 pcs or less, 8.0×10 10 pcs or more 3.0×10 11 1 or fewer, or 8.0 × 10 10 pcs or more 2.0×10 11 The number may be less than or equal to 5.0 × 10¹⁶. The daily dose of the composition according to this embodiment (for example, the daily dose for an adult) is based on the number of lactic acid bacteria, for example, 5.0 × 10¹⁶. 10 pcs or more 3.0×10 11 1 or fewer, or 8.0 × 10 10 pcs or more 2.0×10 11 When the number is below a certain threshold, improvement of eye and nasal symptoms and / or prevention of their onset or worsening can be effectively achieved. The number of lactic acid bacteria can be measured using a known microscope, flow cytometer, or non-cultured microbial rapid testing device (e.g., ELESTA PixeeMo (AFI Technology Co., Ltd.)), but from the standpoint of high versatility, it may also be measured by microscope.

[0072] The daily dose of the composition according to this embodiment is not particularly limited, but can be determined, for example, by the dry cell mass of lactic acid bacteria. The daily dose of the composition according to this embodiment (for example, the daily dose for an adult) is, for example, 2.5 × 10⁻⁶ -2 mg or more, 2.5×10 -1 It may be mg or more, 2.5 mg or more, 2.5 × 10 mg or more, 3.5 × 10 mg or more, or 5.0 × 10 mg or more, 2.5 × 10 4 mg or less, 2.5×10 3 mg or less, 2.5×10 2 mg or less, 1.0×10 2 The dose may be less than or equal to mg or less than or equal to 8.0 × 10 mg, and these upper and lower limits can be arbitrarily combined. The daily dose of the composition according to this embodiment (for example, the daily dose for an adult) is, for example, 2.5 × 10 -2 mg or more 2.5×10 4 mg or less, 2.5×10 -2 mg or more 2.5×10 3 mg or less, 2.5×10 -2 mg or more 2.5×10 2 mg or less, 2.5×10 -2 mg or more 1.0×10 2 mg or less, 2.5×10 -2 mg or more, 8.0 x 10 mg or less, 2.5 x 10 -1 mg or more 2.5×10 4 mg or less, 2.5×10 -1 mg or more 2.5×10 3 mg or less, 2.5×10 -1 mg or more 2.5×10 2 mg or less, 2.5×10 -1 mg or more 1.0×10 2 mg or less, 2.5×10 -1 mg or more and 8.0 x 10 mg or less, 2.5 mg or more and 2.5 x 10 4 mg or less, 2.5 mg or more 2.5×10 3 mg or less, 2.5 mg or more 2.5×10 2 mg or less, 2.5 mg or more 1.0×10 2 mg or less, 2.5 mg or more and 8.0 × 10 mg or less, 2.5 × 10 mg or more 2.5 × 10 4 mg or less, 2.5 x 10 mg or more 2.5 x 10 3 mg or less, 2.5 x 10 mg or more 2.5 x 10 2 mg or less, 2.5 x 10 mg or more 1.0 x 10 2 mg or less, 2.5 x 10 mg or more and 8.0 x 10 mg or less, 3.5 x 10 mg or more and 2.5 x 10 4 mg or less, 3.5 x 10 mg or more 2.5 x 10 3 mg or less, 3.5 x 10 mg or more 2.5 x 10 2 mg or less, 3.5 x 10 mg or more 1.0 x 10 2 mg or less, 3.5 x 10 mg or more and 8.0 x 10 mg or less, 5.0 x 10 mg or more 2.5 x 10 4 mg or less, 5.0 x 10 mg or more 2.5 x 10 3 mg or less, 5.0 x 10 mg or more 2.5 x 10 2 mg or less, 5.0 x 10 mg or more 1.0 x 10 2 It may be 5.0 × 10 mg or less, or 8.0 × 10 mg or more.

[0073] The composition according to this embodiment is preferably administered continuously for the period during which improvement of eye and nasal symptoms and / or prevention of their onset or worsening are expected. The administration period of the composition according to this embodiment is not particularly limited from the viewpoint of better exhibiting improvement of eye and nasal symptoms and / or prevention of their onset or worsening, but for example it can be 7 days or more, 14 days or more, 21 days or more, preferably 28 days or more, 42 days or more, 56 days or more, 70 days or more, or 84 days or more, and it can also be 180 days or less, 150 days or less, 120 days or less, or 90 days or less, and these upper and lower limits may be freely combined. The administration period of the composition according to this embodiment is, for example, 7 days or more and 180 days or less, 7 days or more and 150 days or less, 7 days or more and 120 days or less, 7 days or more and 90 days or less, 14 days or more and 180 days or less, 14 days or more and 150 days or less, 14 days or more and 120 days or less, 14 days or more and 90 days or less, 21 days or more and 180 days or less, 21 days or more and 150 days or less, 21 days or more and 120 days or less, 21 days or more and 90 days or less, 28 days or more and 180 days or less, 28 days or more and 150 days or less, 28 days or more and 120 days or less, 28 days or more The administration interval may be 90 days or less, 42 days to 180 days, 42 days to 150 days, 42 days to 120 days, 42 days to 90 days, 56 days to 180 days, 56 days to 150 days, 56 days to 120 days, 56 days to 90 days, 70 days to 180 days, 70 days to 150 days, 70 days to 120 days, 70 days to 90 days, 84 days to 180 days, 84 days to 150 days, 84 days to 120 days, or 84 days to 90 days. Furthermore, the administration interval of the composition according to this embodiment is not particularly limited, but for example it may be 3 days, 2 days, 1 day, or 0 days, and in a preferred embodiment it may be 0 days. In other words, in a preferred embodiment, the composition according to this embodiment may be administered daily.

[0074] The composition according to this embodiment may be administered before an event or time in which improvement of eye and nasal symptoms and / or prevention of their onset or worsening are expected. In one embodiment, the event in which improvement of eye and nasal symptoms and / or prevention of their onset or worsening are expected may be exposure to pollen. The composition according to this embodiment may be administered 1 day or more, 3 days or more, 7 days or more, 14 days or more, or 21 days or more before the day the subject is exposed to pollen, and may also be administered less than 28 days, less than 24 days, less than 17 days, less than 10 days, less than 6 days, less than 4 days, or less than 2 days before, and these upper and lower limits can be freely combined. In other words, the composition according to this embodiment may be used to be administered a predetermined number of days before the day on which pollen dispersal begins and before the day on which pollen dispersal begins, and the predetermined number of days may be 1 day or more, 3 days or more, 7 days or more, 14 days or more, or 21 days or more, and may be less than 28 days, less than 24 days, less than 17 days, less than 10 days, less than 6 days, less than 4 days, or less than 2 days, and these upper and lower limits can be freely combined. The composition according to this embodiment may be administered starting, for example, 1 day or more but less than 28 days before the day the subject is exposed to pollen, 1 day or more but less than 24 days before, 1 day or more but less than 17 days before, 1 day or more but less than 10 days before, 1 day or more but less than 6 days before, 1 day or more but less than 4 days before, 1 day or more but less than 2 days before, 3 days or more but less than 28 days before, 3 days or more but less than 24 days before, 3 days or more but less than 17 days before, 3 days or more but less than 10 days before, 3 days or more but less than 6 days before, 3 days or more but less than 4 days before, 7 days or more but less than 28 days before, 7 days or more but less than 24 days before, 7 days or more but less than 17 days before, 7 days or more but less than 10 days before, 14 days or more but less than 28 days before, 14 days or more but less than 24 days before, 14 days or more but less than 17 days before, 21 days or more but less than 28 days before, or 21 days or more but less than 24 days before.

[0075] In a preferred embodiment, if administration of the composition according to this embodiment is initiated before an event or time in which improvement of eye and nasal symptoms and / or prevention of their onset or worsening is expected, the composition may be administered until after the event or time in which improvement of the eye and nasal symptoms and / or prevention of their onset or worsening is expected. In this case, the administration period may be, for example, 28 days or more, 42 days or more, 56 days or more, 70 days or more, or 84 days or more, and may also be 180 days or less, 150 days or less, 120 days or less, or 90 days or less, and these upper and lower limits can be freely combined, for example, 28 days or more and 180 days or less, 28 days or more and 150 days or less, 28 days or more and 120 days or less, 28 days or more and 90 days or less, 42 days or more and 180 days or less, 42 days or less and 42 days or less The period may be 150 days or less, 42 days or more and 120 days or less, 42 days or more and 90 days or less, 56 days or more and 180 days or less, 56 days or more and 150 days or less, 56 days or more and 120 days or less, 56 days or more and 90 days or less, 70 days or more and 180 days or less, 70 days or more and 150 days or less, 70 days or more and 120 days or less, 70 days or more and 90 days or less, 84 days or more and 180 days or less, 84 days or more and 150 days or less, 84 days or more and 120 days or less, or 84 days or more and 90 days or less.Furthermore, in this case, the administration period may continue for 7 days or more, 14 days or more, 21 days or more, preferably 28 days or more, 42 days or more, 56 days or more, 70 days or more, or 84 days or more, from the start of the event or time when improvement of the above-mentioned eye and nose symptoms and / or prevention of their onset or worsening is expected, and may be 180 days or less, 150 days or less, 120 days or less, 90 days or less, 75 days or less, 60 days or less, 50 days or less, 40 days or less, or 30 days or less, and these upper and lower limits can be freely combined, for example 7 days or more and 180 days or less, 7 days or more and 150 days or less, 7 days or more and 120 days or less, 7 days or more and 90 days or less, 7 days or more and 75 days or less, 7 days or more and 60 days or less, 7 days or more and 50 days or less, 7 days or more and 40 days or less, 7 days or more and 30 days or less, 14 days or more and 180 days or less, 14 days or more and 150 days or less, 14 days or more and 120 days or less, 14 days or more and 90 days or less, 14 days or more and 75 days or less, 14 days or more and 60 days or less, 14 days or more and 50 days or less, 14 days or more and 40 days or less, 14 days or more and 30 days or less, 21 days or more and 180 days or less, 21 days or more and 150 days or less, 2 1 day to 120 days, 21 days to 90 days, 21 days to 75 days, 21 days to 60 days, 21 days to 50 days, 21 days to 40 days, 21 days to 30 days, 28 days to 180 days, 28 days to 150 days, 28 days to 120 days The following: 28 days to 90 days, 28 days to 75 days, 28 days to 60 days, 28 days to 50 days, 28 days to 40 days, 28 days to 30 days, 42 days to 180 days, 42 days to 150 days, 42 days to 120 days, 42 days or more It may be 90 days or less, 42 days or more and 75 days or less, 42 days or more and 60 days or less, 42 days or more and 50 days or less, 56 days or more and 180 days or less, 56 days or more and 150 days or less, 56 days or more and 120 days or less, 56 days or more and 90 days or less, 56 days or more and 75 days or less, 56 days or more and 60 days or less, 70 days or more and 180 days or less, 70 days or more and 150 days or less, 70 days or more and 120 days or less, 70 days or more and 90 days or less, 84 days or more and 180 days or less, 84 days or more and 150 days or less, 84 days or more and 120 days or less, or 84 days or more and 90 days or less.

[0076] In a preferred embodiment, the composition according to this embodiment may be administered for a period such that the maximum daily pollen count measured by the Durham method from the start of administration to a predetermined number of days falls within a predetermined range. The Durham method is a method for evaluating the number of pollen grains in the air using the number of pollen grains attached to a slide glass coated with petrolatum after it has been left outdoors for 24 hours as an indicator. The number of pollen grains attached to the slide glass can be counted, for example, by visual inspection using a microscope. The predetermined number of days from the start of administration may be, for example, 7 days or 14 days. The number of days may be 21, 28, 35, 42, 49, or 56, and preferably 28. The pollen count may be the pollen count in the region including the point where the composition according to this embodiment is administered (administration point), and may be, for example, the average pollen count in the country to which the administration point belongs, the administrative unit to which the administration point belongs (e.g., prefecture, city, town, state, county, city, town, village, Bundesland, county, city, town, region, county, district, borough, department, commune, province, municipality, autonomous region, prefecture-level city, or township), or within a 100km radius from the administration point, or the measured pollen count at a fixed observation point belonging to that region. The specified range for the number of dispersed pollen grains is, for example, 1 grain / cm³. 2 More than or 10 pieces / cm 2 The above is sufficient, and 220 pieces / cm 2 Below, 180 pieces / cm 2 Below, 140 pieces / cm 2 Below, 100 pieces / cm 2 Below or 60 pieces / cm 2 The following limits may also apply, and these upper and lower limits may be freely combined, for example, 1 unit / cm². 2 More than 220 pieces / cm 2 Below, 1 piece / cm 2 More than 180 pieces / cm 2 Below, 1 piece / cm 2 More than 140 pieces / cm 2 Below, 1 piece / cm 2 More than 100 pieces / cm 2 Below, 1 piece / cm 2 More than 60 pieces / cm 2 Below, 10 pieces / cm 2 More than 220 pieces / cm 2 Below, 10 pieces / cm 2 More than 180 pieces / cm 2 Below, 10 pieces / cm 2 More than 140 pieces / cm 2 Below, 10 pieces / cm 2 More than 100 pieces / cm 2 The following, or 10 pieces / cm 2 More than 60 pieces / cm 2 The following may be the case, for example, 1 piece / cm 2 More than 220 pieces / cm 2 The following is also acceptable.

[0077] If the composition according to this embodiment is a food composition, the food composition may contain lactic acid bacteria in an effective amount. In other words, the food composition may contain lactic acid bacteria as an active ingredient. Here, "containing in an effective amount" means that when the amount normally consumed in each food composition is taken, the active ingredient of the present invention is taken in such an amount that it exhibits effects such as improvement of eye and nose symptoms and / or prevention of their onset or worsening. The term "food composition" is used to include health foods, functional foods, nutritional supplements, health functional foods (e.g., Foods for Specified Health Uses, Foods with Nutrient Function Claims, Foods with Function Claims), foods for special dietary uses (e.g., foods for infants, foods for pregnant and lactating women, foods for the sick), and supplements. Furthermore, in the case of Foods for Specified Health Uses, the active ingredient may be the active ingredient. In the case of Foods with Nutrient Function Claims, the nutritional component may be the active ingredient. In the case of Foods with Function Claims, the functionally active ingredient may be the active ingredient.

[0078] The composition according to this embodiment has effects such as improving eye and nose symptoms and / or preventing their onset or worsening, and can therefore be provided by being included in food consumed on a daily basis. In this case, the composition according to this embodiment can be provided in a unit package form in which the amount to be consumed per serving is predetermined. The unit package form per serving is not particularly limited, but examples include a form that specifies a fixed amount in a pack, packaging, can or bottle. In order to better exert the various effects of the composition according to this embodiment, the amount to be consumed per serving may be determined according to the daily dose of lactic acid bacteria as described above. The food according to this embodiment may be provided with information regarding the amount to be consumed displayed on the packaging, or together with a document containing such information.

[0079] The predetermined intake amount per serving in the unit packaging form may be the effective daily intake amount, or it may be the effective daily intake amount divided into two or more (preferably two to six) doses. Therefore, the unit packaging form of the composition according to this embodiment can contain the active ingredient of the present invention in the amount of the daily intake amount described later, or it can contain the active ingredient of the present invention in an amount of one-half to one-sixth of the amount of the daily intake amount described later. For the convenience of intake, it is preferable to provide the composition according to this embodiment in a unit packaging form per serving (i.e., a unit packaging form per day) in which the intake amount per serving is the effective daily intake amount.

[0080] The form of the "food composition" in the composition according to this embodiment is not particularly limited, but may be, for example, in the form of a beverage, a semi-liquid or gel-like form, a solid or powder-like form. Examples of "supplements" include tablets produced by kneading the active ingredient of the composition according to this embodiment with excipients, binders, etc., and then compressing them; granules produced by granulating the active ingredient with excipients, binders, etc.; orally disintegrating tablets; and capsules containing the active ingredient enclosed in capsules, etc. When providing as a supplement, in addition to the above-mentioned per-serving or per-day unit packaging, it is also preferable to provide it in per-week, per-two-week, per-month, or per-two-month unit packaging. The latter unit packaging is not particularly limited, but it is preferable, for example, to display the amount to be consumed per serving or per day, so that the consumer can effectively ingest the active ingredient of the present invention according to that indication. Furthermore, from the viewpoint of the absorption of the active ingredients into the body, the food composition of the present invention is preferably a supplement, more preferably a tablet, and in one embodiment, it is even more preferably a lozenge tablet (a tablet that is sucked on and dissolved in the mouth to allow absorption of the drug's components), and in one embodiment, it is even more preferably a sublingual tablet (a tablet that is placed under the tongue and dissolved to allow absorption of the drug's components).

[0081] If the food composition provided as a composition according to this embodiment is a health food, functional food, nutritional composition, nutritional supplement, supplement, health food, food for specified health uses, food with nutritional function claims, or food with functional claims, such a food composition is not particularly limited, but for example, it may be labeled as follows. • "For those with allergy symptoms" • "For those experiencing itching around the eyes and nose" • "For those experiencing hay fever symptoms" • "To improve the quality of life for people suffering from hay fever symptoms." • "To alleviate discomfort in the eyes and nose during the initial pollen season." • "Relieves discomfort in the eyes and nose caused by pollen, dust, house dust, etc." • "Reducing disruption to outdoor activities caused by pollen, dust, house dust, etc." • "Relieves eye and nasal discomfort caused by pollen, dust, and house dust, and reduces the disruption to outdoor life." • "By maintaining a healthy immune balance, it relieves eye and nasal discomfort caused by pollen, dust, and house dust, and reduces the disruption to outdoor life." • "For those who want to reduce the disruption to studying, working, and doing household chores during allergy season." • "For those who want to alleviate mental concentration problems during allergy season." • "For those who want to alleviate the decline in cognitive function (difficulty organizing thoughts) during allergy season." • "For those who want to reduce the difficulties (inconveniences) of reading newspapers or books during allergy season." • "For those who want to alleviate memory loss (poor memory) during allergy season." • "For those who want to reduce the disruption to outdoor activities such as sports and picnics during allergy season." • "For those who want to reduce the inconvenience (of avoiding going out) during allergy season." • "For those who want to reduce the difficulties (such as being withdrawn) in social interactions during allergy season." • "For those who want to reduce the difficulty of conversing or talking on the phone with others during allergy season." • "For those who want to alleviate the discomfort that others might notice during allergy season." • "For those who want to alleviate sleep disturbances (poor sleep) during allergy season." • "For those who want to alleviate fatigue during allergy season." • "For those who want to reduce fatigue (easily get tired) during allergy season." • "For those who want to alleviate their gloomy mood during allergy season." • "For those who want to reduce irritability during allergy season." • "For those who want to alleviate depression during allergy season." • "For those who want to alleviate dissatisfaction with their daily lives during allergy season."

[0082] The food composition provided as a composition according to this embodiment is not particularly limited as long as it contains an active ingredient, but examples include: soft drinks, carbonated drinks, fruit juice drinks, vegetable juice drinks, fruit and vegetable juice drinks, milk and other dairy products, soy milk, dairy beverages, drinkable yogurt, drinkable or stick-type jelly, coffee, cocoa, tea beverages, nutritional drinks, energy drinks, sports drinks, mineral water (including both sparkling and non-sparkling), near water, non-alcoholic beverages such as non-alcoholic beer-flavored beverages; carbohydrate-containing foods and beverages such as rice dishes, noodles, bread or pasta; cheeses, hard or soft yogurt, fresh cream made from dairy products or other oil and fat raw materials, etc. Dairy products such as ice cream; Western-style confectionery such as cookies, cakes, and chocolates; Japanese-style confectionery such as manju or yokan; tablet candies such as ramune (refreshing candies); candies, gums, gummies, frozen desserts such as jelly or pudding; various confectionery such as snack foods; alcoholic beverages such as whiskey, bourbon, spirits, liqueurs, wine, fruit wine, sake, Chinese liquor, shochu, beer, non-alcoholic beer with an alcohol content of 1% or less, sparkling wine, other miscellaneous alcoholic beverages, and chuhai; processed foods using eggs, processed foods of seafood or meat (including offal such as liver) (including delicacies), processed foods such as soups such as miso soup, seasonings such as miso, soy sauce, furikake, and other seasonings, or liquid foods such as concentrated liquid foods.

[0083] Tea beverages include, but are not particularly limited to, fermented teas, semi-fermented teas, and unfermented teas. Examples include black tea, green tea, barley tea, brown rice tea, sencha, gyokuro tea, hojicha, oolong tea, turmeric tea, pu-erh tea, rooibos tea, rose tea, chrysanthemum tea, ginkgo leaf tea, and herbal teas (e.g., mint tea, jasmine tea).

[0084] The fruits used in fruit juice beverages and beverages containing both fruit and vegetable juices are not particularly limited, but examples include apples, oranges, grapes, bananas, pears, peaches, mangoes, acai, blueberries, and plums. Similarly, the vegetables used in vegetable juice beverages and beverages containing both fruit and vegetable juices are not particularly limited, but examples include tomatoes, carrots, celery, pumpkins, cucumbers, and watermelons.

[0085] When the composition according to this embodiment is provided as a pharmaceutical composition or quasi-drug, it can be formulated as an oral or parenteral preparation. Examples of oral preparations include granules, powders, tablets (including sugar-coated tablets), pills, capsules, syrups, liquids, jellies, emulsions, and suspensions. For example, it may be a tablet, and in one embodiment it may be a lozenge (a tablet that is licked and dissolved in the mouth to allow absorption of the drug's components), and in another embodiment it may be a sublingual tablet (a tablet that is placed under the tongue and dissolved to allow absorption of the drug's components). Examples of parenteral preparations include injections suitable for local administration (including intradermal, subcutaneous, intramuscular, and intravenous injections), inhalants (e.g., inhalation aerosols, inhalation powders, inhalation solutions), nasal drops (e.g., nasal powders, nasal solutions), ointments, creams, gels, suppositories, patches, and compresses. These preparations can be formulated using pharmaceutically acceptable carriers by methods commonly used in the art. Pharmaceutically acceptable carriers include excipients, binders, diluents, additives, fragrances, buffers, thickeners, colorants, stabilizers, emulsifiers, dispersants, suspending agents, and preservatives.

[0086] In a preferred embodiment, the composition according to this embodiment is administered to a human at a dose of 5.0 × 10 per day. 10 pcs or more 3.0×10 11 It may be used so that fewer than 10 lactic acid bacteria are administered orally. In a more preferred embodiment, the composition according to this embodiment is administered to humans at a dose of 8.0 × 10 per day. 10 pcs or more 2.0×10 11 The composition according to this embodiment may be used to administer orally with a dose of 1 or fewer lactic acid bacteria. When the composition according to this embodiment is used in this manner, eye and nasal symptoms are suitably improved in the administered person. Furthermore, when the composition according to this embodiment is used in this manner, the onset or worsening of eye and nasal symptoms is suitably prevented in the administered person.

[0087] In one preferred embodiment, the composition according to this embodiment may be administered orally for a period of 28 days or more, starting from 28 days before the start of pollen dispersal and before the start of pollen dispersal. In another preferred embodiment, the composition according to this embodiment is used when the maximum number of pollen grains per day measured by the Durham method from the start of administration to day 28 of administration is 1 grain / cm³. 2 More than 220 pieces / cm 2 The composition according to this embodiment may be used for oral administration during the following period. When the composition according to this embodiment is used in this manner, eye and nasal symptoms are suitably improved in the administered person, and eye and nasal symptoms are suitably improved, particularly at the beginning of the pollen season. Furthermore, when the composition according to this embodiment is used in this manner, the onset or worsening of eye and nasal symptoms is suitably prevented in the administered person, and eye and nasal symptoms are suitably prevented, particularly at the beginning of the pollen season. In these cases, the pollen may be, for example, cedar or cypress pollen. The number of pollen grains dispersed may be, for example, the sum of the number of cedar and cypress pollen grains dispersed. The fact that the composition according to this embodiment is used in this manner may be described, for example, on the product packaging or website, or in an instruction manual or accompanying document, which may be in electronic format. One aspect of this embodiment may be a kit comprising the composition according to this embodiment and a package, instruction manual or accompanying document describing how the composition is used as described above.

[0088] Another embodiment of the present disclosure is a method for improving and / or preventing the onset or worsening of eye and / or nasal symptoms, which involves administering a composition containing lactic acid bacteria to a subject, the details of which are described above with respect to the composition of the first embodiment.

[0089] <Methods to improve eye and nasal symptoms and / or prevent their onset or worsening> A second embodiment of this disclosure relates to a method for improving and / or preventing the onset or worsening of eye and nasal symptoms, comprising administering lactic acid bacteria to a subject. The lactic acid bacteria may be contained in, for example, the composition of the first embodiment described above. Alternatively, the second embodiment of this disclosure may also be described as a method comprising administering lactic acid bacteria to a subject and improving the above-mentioned eye and / or nasal symptoms in the subject, the method being, for example, a method for improving and / or preventing the onset or worsening of eye and nasal symptoms.

[0090] The dosage of lactic acid bacteria can be determined depending on the recipient's sex, age and weight, symptoms, administration time, dosage form, route of administration, and the materials or drugs used in combination. The daily dose of lactic acid bacteria (e.g., the daily dose for adults) is not particularly limited, but for example, 1.0 × 10⁻⁶ 5 pcs or more, 3.0×10 5 pcs or more, 1.0×10 6 pcs or more, 3.0×10 6 pcs or more, 1.0×10 7 pcs or more, 3.0×10 7 pcs or more, 1.0×10 8 pcs or more, 3.0×10 8 pcs or more, 5.0×10 8 pcs or more, 1.0×10 9 pcs or more, 5.0×10 9 pcs or more, 1.0×10 10 pcs or more, 5.0×10 10 One or more or 8.0 × 10 10 There may be more than 1.0 × 10 14 pcs or less, 1.0×10 13 pcs or less, 1.0×10 12 pcs or less, 3.0×10 11 1 or less or 2.0 × 10 11 The number may be less than or equal to 10. Furthermore, these upper and lower limits can be combined in any way and are not particularly limited. For example, the daily dose of lactic acid bacteria (e.g., the daily dose for adults) is not particularly limited, but 1.0 × 10 5 pcs or more 1.0×10 14 Less than 1.0 × 10 5 More than 1.0 × 10 13 Less than 1.0 × 10 5 More than 1.0 × 10 12 Less than 1.0 × 10 5 More than 3.0 × 10 11 Less than 1.0 × 10 5 More than 2.0 × 10 11 Less than 3.0 × 10 5 More than 1.0 × 10 14 Less than 3.0 × 10 5 More than 1.0 × 10 13 Less than 3.0 × 10 5 More than 1.0 × 10 12 Less than 3.0 × 10 5 More than 3.0 × 10 11 Less than 3.0 × 10 5 More than 2.0 × 10 11 Less than 1.0 × 10 6 More than 1.0 × 10 14 Less than 1.0 × 10 6 More than 1.0 × 10 13 Less than 1.0 × 10 6 More than 1.0 × 10 12 Less than 1.0 × 10 6 More than 3.0 × 10 11 Less than 1.0 × 10 6 More than 2.0 × 10 11 Less than 3.0 × 10 6 More than 1.0 × 10 14 Less than 3.0 × 10 6 More than 1.0 × 10 13 Less than 3.0 × 10 6 More than 1.0 × 10 12 Less than 3.0 × 10 6 More than 3.0 × 10 11 Less than 3.0 × 10 6 More than 2.0 × 10 11 Less than 1.0 × 10 7 More than 1.0 × 10 14 Less than 1.0 × 10 7 More than 1.0 × 10 13 Less than 1.0 × 10 7 More than 1.0 × 10 12 Less than 1.0 × 10 7 More than 3.0 × 10 11 Less than 1.0 × 10 7 More than 2.0 × 10 11 Less than 3.0 × 10 7 More than 1.0 × 10 14 Less than 3.0 × 10 7 More than 1.0 × 10 13 Less than 3.0 × 10 7 More than 1.0 × 10 12 Less than 3.0 × 10 7 More than 3.0 × 10 11 Less than 3.0 × 10 7 More than 2.0 × 10 11 Less than 1.0 × 10 8 More than 1.0 × 10 14 Less than 1.0 × 10 8 More than 1.0 × 10 13 Less than 1.0 × 10 8 More than 1.0 × 10 12 Less than 1.0 × 10 8 More than 3.0 × 10 11 Less than 1.0 × 10 8 More than 2.0 × 10 11 Less than 3.0 × 10 8 More than 1.0 × 10 14 Less than 3.0 × 10 8 More than 1.0 × 10 13 Less than 3.0 × 10 8 More than 1.0 × 10 12 Less than 3.0 × 10 8 More than 3.0 × 10 11 Less than 3.0 × 10 8 More than 2.0 × 10 11 Less than 5.0 × 10 8 More than 1.0 × 10 14 Less than 5.0 × 10 8 More than 1.0 × 10 13 Less than 5.0 × 10 8 More than 1.0 × 10 12 Less than 5.0 × 10 8 More than 3.0 × 10 11 Less than 5.0 × 10 8 More than 2.0 × 10 11 Less than 1.0 × 10 9 More than 1.0 × 10 14 Less than 1.0 × 10 9 More than 1.0 × 10 13 Less than 1.0 × 10 9 More than 1.0 × 10 12 Less than 1.0 × 10 9 More than 3.0 × 10 11 Less than 1.0 × 10 9 More than 2.0 × 10 11 Less than 5.0 × 10 9 More than 1.0 × 10 14 Less than 5.0 × 10 9 More than 1.0 × 10 13 Less than 5.0 × 10 9 More than 1.0 × 10 12 Less than 5.0 × 10 9 More than 3.0 × 10 11 Less than 5.0 × 10 9 More than 2.0 × 10 11 Less than 1.0 × 10 10 More than 1.0 × 10 14 Less than 1.0 × 10 10 More than 1.0 × 10 13 Less than 1.0 × 10 10 More than 1.0 × 10 12 Less than 1.0 × 10 10 More than 3.0 × 10 11 Less than 1.0 × 10 10 More than 2.0 × 10 11 Less than 5.0 × 10 10 More than 1.0 × 10 14 Less than 5.0 × 10 10 More than 1.0 × 10 13 Less than 5.0 × 10 10 More than 1.0 × 10 12 Less than 5.0 × 10 10 More than 3.0 × 10 11 Less than 5.0 × 10 10 More than 2.0 × 10 11 Less than 8.0 × 10 10 More than 1.0 × 10 14 Less than 8.0 × 10 10 More than 1.0 × 10 13 Less than 8.0 × 10 10 pcs or more 1.0×10 12 pcs or less, 8.0×10 10 pcs or more 3.0×10 11 1 or fewer, or 8.0 × 10 10 pcs or more 2.0×10 11 It may be less than or equal to 10. The daily dose of lactic acid bacteria (for example, the daily dose for adults) is based on the number of lactic acid bacteria, for example, 5.0 × 10. 10 pcs or more 3.0×10 11 1 or fewer, or 8.0 × 10 10 pcs or more 2.0×10 11 When the number is below a certain threshold, improvement of eye and nasal symptoms and / or prevention of their onset or worsening can be effectively achieved. The number of lactic acid bacteria can be measured using a known microscope, flow cytometer, or non-cultured microbial rapid testing device (e.g., ELESTA PixeeMo (AFI Technology Co., Ltd.)), but from the standpoint of high versatility, it may also be measured by microscope.

[0091] The daily dose of lactic acid bacteria is not particularly limited, but can be determined, for example, by the dry cell mass of the lactic acid bacteria. The daily dose of lactic acid bacteria (for example, the daily dose for adults) is, for example, 2.5 × 10⁻⁶. -2 mg or more, 2.5×10 -1 It may be mg or more, 2.5 mg or more, 2.5 × 10 mg or more, 3.5 × 10 mg or more, or 5.0 × 10 mg or more, 2.5 × 10 4 mg or less, 2.5×10 3 mg or less, 2.5×10 2 mg or less, 1.0×10 2 The dose may be less than or equal to mg, or less than or equal to 8.0 × 10 mg, and these upper and lower limits can be combined arbitrarily. The daily dose of lactic acid bacteria (for example, the daily dose for adults) is, for example, 2.5 × 10 -2 mg or more 2.5×10 4 mg or less, 2.5×10 -2 mg or more 2.5×10 3 mg or less, 2.5×10 -2 mg or more 2.5×10 2 mg or less, 2.5×10 -2 mg or more 1.0×10 2 mg or less, 2.5×10 -2 mg or more, 8.0 x 10 mg or less, 2.5 x 10 -1 mg or more 2.5×10 4 mg or less, 2.5×10 -1 mg or more 2.5×10 3 mg or less, 2.5×10 -1 mg or more 2.5×10 2 mg or less, 2.5×10 -1 mg or more 1.0×10 2 mg or less, 2.5×10 -1 mg or more and 8.0 x 10 mg or less, 2.5 mg or more and 2.5 x 10 4 mg or less, 2.5 mg or more 2.5×10 3 mg or less, 2.5 mg or more 2.5×10 2 mg or less, 2.5 mg or more 1.0×10 2 mg or less, 2.5 mg or more and 8.0 × 10 mg or less, 2.5 × 10 mg or more 2.5 × 10 4 mg or less, 2.5 x 10 mg or more 2.5 x 10 3 mg or less, 2.5 x 10 mg or more 2.5 x 10 2 mg or less, 2.5 x 10 mg or more 1.0 x 10 2 mg or less, 2.5 x 10 mg or more and 8.0 x 10 mg or less, 3.5 x 10 mg or more and 2.5 x 10 4 mg or less, 3.5 x 10 mg or more 2.5 x 10 3 mg or less, 3.5 x 10 mg or more 2.5 x 10 2 mg or less, 3.5 x 10 mg or more 1.0 x 10 2 mg or less, 3.5 x 10 mg or more and 8.0 x 10 mg or less, 5.0 x 10 mg or more 2.5 x 10 4 mg or less, 5.0 x 10 mg or more 2.5 x 10 3 mg or less, 5.0 x 10 mg or more 2.5 x 10 2 mg or less, 5.0 x 10 mg or more 1.0 x 10 2 It may be 5.0 × 10 mg or less, or 8.0 × 10 mg or more.

[0092] The form of administration of lactic acid bacteria is not particularly limited, but from the viewpoint of reducing the burden on the recipient, oral administration is preferred, and oral ingestion is more preferred. When used for oral administration, the lactic acid bacteria and / or compositions containing them may have high resistance to gastric juice and intestinal juice, etc., and are not particularly limited, but for example, it is preferable that they have strong acid resistance.

[0093] The recipients of the lactic acid bacteria may be humans and / or non-human mammals, and may be humans.

[0094] Lactic acid bacteria may be administered to subjects who need them. These subjects may be, for example, subjects who need improvement of eye and nasal symptoms and / or prevention of their onset or worsening. Subjects to whom lactic acid bacteria are administered may be, for example, subjects who have eye and nasal symptoms and / or allergies, and / or subjects who have the possibility and / or risk of having them, and may be subjects who have eye and nasal symptoms and / or allergies. Subjects who have eye and nasal symptoms may preferably be subjects who have mild to moderate eye and nasal symptoms. Subjects who have allergies may preferably be subjects with allergic ophthalmorhinoitis or hay fever. More preferably, subjects to whom lactic acid bacteria are administered may be subjects with mild to moderate allergic ophthalmorhinoitis. The severity classification of allergic rhinitis symptoms, such as mild and moderate, is not particularly limited, but can be done, for example, by the method described in the examples. Specifically, in accordance with the 2020 Guidelines for the Diagnosis of Rhinitis, an otolaryngologist will evaluate the combination of sneezing or runny nose and the severity of nasal congestion on a five-point scale: "most severe," "severe," "moderate," "mild," and "asymptomatic." The scores will then be calculated and tallied as follows: "Most severe: 4 points," "Severe: 3 points," "Moderate: 2 points," "Mild: 1 point," and "Asymptomatic: 0 points."

[0095] It is preferable to continue administering lactic acid bacteria for the period during which improvement of eye and nasal symptoms and / or prevention of their onset or worsening are expected. The administration of lactic acid bacteria is not particularly limited from the viewpoint of better demonstrating the improvement of eye and nasal symptoms and / or prevention of their onset or worsening, but for example it can be 7 days or more, 14 days or more, 21 days or more, preferably 28 days or more, 42 days or more, 56 days or more, 70 days or more, or 84 days or more, and it can also be 180 days or less, 150 days or less, 120 days or less, or 90 days or less, and these upper and lower limits may be freely combined. The duration of lactic acid bacteria administration is, for example, 7 to 180 days, 7 to 150 days, 7 to 120 days, 7 to 90 days, 14 to 180 days, 14 to 150 days, 14 to 120 days, 14 to 90 days, 21 to 180 days, 21 to 150 days, 21 to 120 days, 21 to 90 days, 28 to 180 days, 28 to 150 days, 28 to 120 days, and 28 to 90 days. The following intervals may be 42 to 180 days, 42 to 150 days, 42 to 120 days, 42 to 90 days, 56 to 180 days, 56 to 150 days, 56 to 120 days, 56 to 90 days, 70 to 180 days, 70 to 150 days, 70 to 120 days, 70 to 90 days, 84 to 180 days, 84 to 150 days, 84 to 120 days, or 84 to 90 days. Furthermore, the administration interval of lactic acid bacteria is not particularly limited, but for example it may be 3 days, 2 days, 1 day, or 0 days, and in a preferred embodiment it may be 0 days. In other words, in a preferred embodiment, lactic acid bacteria may be administered daily.

[0096] Lactic acid bacteria may be administered before an event or time in which improvement of eye and nasal symptoms and / or prevention of their onset or worsening are expected. In one embodiment, the event in which improvement of eye and nasal symptoms and / or prevention of their onset or worsening may be exposure to pollen. Lactic acid bacteria may be administered at least one day, three days, seven days, fourteen days, or twenty-one days before the day the subject is exposed to pollen, and may also be administered less than 28 days, less than 24 days, less than 17 days, less than 10 days, less than 6 days, less than 4 days, or less than 2 days before, and these upper and lower limits can be freely combined. In other words, lactic acid bacteria may be administered a predetermined number of days before the start of pollen dispersal and before the start of the pollen dispersal, and the predetermined number of days may be 1 day or more, 3 days or more, 7 days or more, 14 days or more, or 21 days or more, and may be less than 28 days, less than 24 days, less than 17 days, less than 10 days, less than 6 days, less than 4 days, or less than 2 days, and these upper and lower limits can be freely combined. Lactic acid bacteria may be administered starting at, for example, 1 day or more but less than 28 days before the day the subject is exposed to pollen, 1 day or more but less than 24 days before, 1 day or more but less than 17 days before, 1 day or more but less than 10 days before, 1 day or more but less than 6 days before, 1 day or more but less than 4 days before, 1 day or more but less than 2 days before, 3 days or more but less than 28 days before, 3 days or more but less than 24 days before, 3 days or more but less than 17 days before, 3 days or more but less than 10 days before, 3 days or more but less than 6 days before, 3 days or more but less than 4 days before, 7 days or more but less than 28 days before, 7 days or more but less than 24 days before, 7 days or more but less than 17 days before, 7 days or more but less than 10 days before, 14 days or more but less than 28 days before, 14 days or more but less than 24 days before, 14 days or more but less than 17 days before, 21 days or more but less than 28 days before, or 21 days or more but less than 24 days before.

[0097] When administering lactic acid bacteria before an event or time in which improvement of eye and nasal symptoms and / or prevention of their onset or worsening are expected, in a preferred embodiment, the lactic acid bacteria may be administered until after the event or time in which improvement of eye and nasal symptoms and / or prevention of their onset or worsening are expected. In this case, the administration period may be, for example, 28 days or more, 42 days or more, 56 days or more, 70 days or more, or 84 days or more, and may also be 180 days or less, 150 days or less, 120 days or less, or 90 days or less, and these upper and lower limits can be freely combined, for example, 28 days or more and 180 days or less, 28 days or more and 150 days or less, 28 days or more and 120 days or less, 28 days or more and 90 days or less, 42 days or more and 180 days or less, 42 days or less The period may be 150 days or less, 42 days or more and 120 days or less, 42 days or more and 90 days or less, 56 days or more and 180 days or less, 56 days or more and 150 days or less, 56 days or more and 120 days or less, 56 days or more and 90 days or less, 70 days or more and 180 days or less, 70 days or more and 150 days or less, 70 days or more and 120 days or less, 70 days or more and 90 days or less, 84 days or more and 180 days or less, 84 days or more and 150 days or less, 84 days or more and 120 days or less, or 84 days or more and 90 days or less.Furthermore, in this case, the administration period may continue for 7 days or more, 14 days or more, 21 days or more, preferably 28 days or more, 42 days or more, 56 days or more, 70 days or more, or 84 days or more, from the start of the event or time when improvement of the above-mentioned eye and nose symptoms and / or prevention of their onset or worsening is expected, and may be 180 days or less, 150 days or less, 120 days or less, 90 days or less, 75 days or less, 60 days or less, 50 days or less, 40 days or less, or 30 days or less, and these upper and lower limits can be freely combined, for example 7 days or more and 180 days or less, 7 days or more and 150 days or less, 7 days or more and 120 days or less, 7 days or more and 90 days or less, 7 days or more and 75 days or less, 7 days or more and 60 days or less, 7 days or more and 50 days or less, 7 days or more and 40 days or less, 7 days or more and 30 days or less, 14 days or more and 180 days or less, 14 days or more and 150 days or less, 14 days or more and 120 days or less, 14 days or more and 90 days or less, 14 days or more and 75 days or less, 14 days or more and 60 days or less, 14 days or more and 50 days or less, 14 days or more and 40 days or less, 14 days or more and 30 days or less, 21 days or more and 180 days or less, 21 days or more and 150 days or less, 2 1 day to 120 days, 21 days to 90 days, 21 days to 75 days, 21 days to 60 days, 21 days to 50 days, 21 days to 40 days, 21 days to 30 days, 28 days to 180 days, 28 days to 150 days, 28 days to 120 days The following: 28 days to 90 days, 28 days to 75 days, 28 days to 60 days, 28 days to 50 days, 28 days to 40 days, 28 days to 30 days, 42 days to 180 days, 42 days to 150 days, 42 days to 120 days, 42 days or more It may be 90 days or less, 42 days or more and 75 days or less, 42 days or more and 60 days or less, 42 days or more and 50 days or less, 56 days or more and 180 days or less, 56 days or more and 150 days or less, 56 days or more and 120 days or less, 56 days or more and 90 days or less, 56 days or more and 75 days or less, 56 days or more and 60 days or less, 70 days or more and 180 days or less, 70 days or more and 150 days or less, 70 days or more and 120 days or less, 70 days or more and 90 days or less, 84 days or more and 180 days or less, 84 days or more and 150 days or less, 84 days or more and 120 days or less, or 84 days or more and 90 days or less.

[0098] In a preferred embodiment, lactic acid bacteria may be administered for a period such that the maximum daily pollen count measured by the Durham method from the start of administration to a predetermined number of days falls within a predetermined range. The number of pollen grains attached to the slide glass can be counted, for example, by visual inspection using a microscope. The predetermined number of days from the start of administration may be, for example, 7, 14, 21, 28, 35, 42, 49, or 56 days, and preferably 28 days. The pollen count may be the pollen count in the area including the location where the lactic acid bacteria are administered (administration site), and may be, for example, the average pollen count in the country to which the administration site belongs, the administrative unit to which the administration site belongs (e.g., prefecture, city, town, state, county, city, town, village, Bundesland, county, city, town, region, county, district, borough, department, commune, province, municipality, autonomous region, prefecture-level city, or township), or within a 100km radius from the administration site, or the measured pollen count at a fixed observation point belonging to that area. The specified range for the number of dispersed pollen grains is, for example, 1 grain / cm³. 2 More than or 10 pieces / cm 2 The above is sufficient, and 220 pieces / cm 2 Below, 180 pieces / cm 2 Below, 140 pieces / cm 2 Below, 100 pieces / cm 2 Below or 60 pieces / cm 2 The following limits may also apply, and these upper and lower limits may be freely combined, for example, 1 unit / cm². 2 More than 220 pieces / cm 2 Below, 1 piece / cm 2 More than 180 pieces / cm 2 Below, 1 piece / cm 2 More than 140 pieces / cm 2 Below, 1 piece / cm 2 More than 100 pieces / cm 2 Below, 1 piece / cm 2 More than 60 pieces / cm 2 Below, 10 pieces / cm 2 More than 220 pieces / cm 2 Below, 10 pieces / cm 2 More than 180 pieces / cm 2 Below, 10 pieces / cm 2 More than 140 pieces / cm 2 Below, 10 pieces / cm 2 More than 100 pieces / cm 2 The following, or 10 pieces / cm 2 More than 60 pieces / cm 2 The following may be the case, for example, 1 piece / cm 2 More than 220 pieces / cm 2 The following is also acceptable.

[0099] In one preferred embodiment, lactic acid bacteria are administered to humans at a dose of 5.0 × 10⁶ per day. 10 pcs or more 3.0×10 11 The above lactic acid bacteria may be administered orally in quantities of 10 or less. In a more preferred embodiment, the lactic acid bacteria may be administered to humans at a dose of 8.0 × 10 per day. 10 pcs or more 2.0×10 11 The above lactic acid bacteria may be administered orally in quantities of less than 1.5. When lactic acid bacteria are administered in this manner, eye and nasal symptoms are suitably improved in the administered person. Furthermore, when the composition according to this embodiment is used in this manner, the onset or worsening of eye and nasal symptoms is suitably prevented in the administered person.

[0100] In one preferred embodiment, the lactic acid bacteria may be administered orally for a period of 28 days or more, starting from 28 days before the start of pollen dispersal and before the start of pollen dispersal. In another preferred embodiment, the lactic acid bacteria may be administered when the maximum daily pollen count measured by the Durham method from the start of administration to day 28 of administration is 1 grain / cm³. 2 More than 220 pieces / cm 2 The above lactic acid bacteria may be administered orally during the following period. When the lactic acid bacteria are administered in this manner, eye and nasal symptoms are suitably improved in the administered person, and eye and nasal symptoms are particularly suitably improved during the initial period of pollen dispersal. Furthermore, when the lactic acid bacteria are used in this manner, the onset or worsening of eye and nasal symptoms is suitably prevented in the administered person, and eye and nasal symptoms are particularly suitably prevented during the initial period of pollen dispersal. In these cases, the pollen may be, for example, cedar or cypress pollen. The pollen count may be, for example, the sum of the pollen counts of cedar and cypress.

[0101] <Use of lactic acid bacteria or compositions containing them> Other embodiments of this disclosure relate to the use of lactic acid bacteria in improving and / or preventing the onset or worsening of eye and / or nasal symptoms. Detailed embodiments of the lactic acid bacteria and their use according to this embodiment may be, for example, those described in the method of the second embodiment described above.

[0102] Further embodiments of this disclosure relate to the use of compositions containing lactic acid bacteria in improving and / or preventing the onset or worsening of symptoms of the eyes and / or nose. Detailed embodiments of compositions and their use according to these embodiments may be, for example, those described with respect to the compositions of the first embodiment described above.

[0103] The use in these embodiments may be non-therapeutic and / or therapeutic, and is preferably non-therapeutic.

[0104] In this disclosure, “therapeutic” use means use in the course of treating the body of a human or animal. Therapeutic use in this disclosure may be, for example, use for the purpose of or in conjunction with a medical practice. Therapeutic use in this disclosure may involve, for example, a medical professional administering the substance to a human or animal, or instructing a human or animal to administer the substance. Therapeutic use in this disclosure may be, for example, use for therapeutic or preventive purposes, use for therapeutic purposes, or use for preventive purposes involving the ingestion of a food composition, or use for therapeutic purposes.

[0105] In this disclosure, “non-therapeutic” use means any use of the substance that does not constitute a therapeutic use. Non-therapeutic use as relating to this disclosure may, for example, be use that is not intended for and / or does not involve a medical procedure. Non-therapeutic use as relating to this disclosure does not, for example, involve a medical professional administering the substance to a human or animal, and / or instructing a human or animal to administer the substance. Non-therapeutic use as relating to this disclosure may, for example, be use for preventive or health-promoting purposes, and may be use for preventive or health-promoting purposes that involves the administration of a pharmaceutical composition or quasi-drug.

[0106] <Lactic acid bacteria or compositions containing them for use> Other embodiments of this disclosure relate to lactic acid bacteria for use in improving and / or preventing the onset or worsening of symptoms of the eyes and / or nose. Detailed embodiments of the lactic acid bacteria and their use according to this embodiment may be, for example, those described in the method of the second embodiment described above. The use in this embodiment is, for example, therapeutic use.

[0107] Further embodiments of this disclosure relate to compositions containing lactic acid bacteria for use in improving and / or preventing the onset or worsening of symptoms of the eyes and / or nose. Detailed aspects of the compositions and their uses according to these embodiments may be, for example, those described for the compositions of the first embodiment described above. The uses in these embodiments are, for example, therapeutic uses.

[0108] <Use of lactic acid bacteria in the manufacture of compositions> Further embodiments of this disclosure relate to the use of lactic acid bacteria in the manufacture of compositions for improving and / or preventing the onset or worsening of eye and / or nasal symptoms. Detailed aspects of compositions according to this embodiment, their manufacture and use may be, for example, those described for the compositions of the first embodiment described above. [Examples]

[0109] The present disclosure will be described in more detail below using examples, but the present disclosure should not be construed as being limited to the following examples.

[0110] <Overview of the exam> A randomized, double-blind, placebo-controlled, parallel-group comparative study was conducted in individuals with mild to moderate allergic rhinitis who experienced eye and nasal discomfort in early spring, were between 20 and 65 years of age, and did not regularly use medication for symptom relief. Participants were given either a food containing L. paracasei KW3110 or a placebo for 12 weeks. The L. paracasei KW3110-containing food contained 140 billion L. paracasei KW3110 cells (50 mg) per daily serving. The L. paracasei KW3110-containing food was administered to subjects once a day, with two tablets dissolving in the mouth for 1-2 minutes. The composition of the test food is shown in Table 1 below.

[0111] [Table 1]

[0112] <Subjects> From among 318 individuals who met the selection criteria (Table 2) and did not violate the exclusion criteria (Table 3) in the preliminary screening (SCR), and who were deemed suitable for participation by the principal investigator, those who tested positive for cedar pollen-specific IgE and whose annual allergy symptoms were classified as mild or moderate on the severity classification of allergic rhinitis symptoms were selected. From these, 120 subjects were selected as participants, aiming for an approximately equal ratio of men and women, based on their high total score on the six questions related to "nasal and ocular symptoms" on the Japanese Standard Quality of Life Questionnaire for Allergic Rhinitis (JRQLQ NO.1). It was also confirmed that the subjects met the selection criteria (Table 2) for healthy individuals or those with mild symptoms.

[0113] [Table 2]

[0114] [Table 3]

[0115] <Allocation> The allocation personnel who assigned subjects to the two groups confirmed that they could not distinguish between the test samples. Subjects were randomly assigned to the two groups using a stratified block randomization method with random numbers, based on gender, age, severity classification of allergic rhinitis symptoms (1. mild, 2. moderate), and the total score of the six questions on "nasal and ocular symptoms" from the Japanese Standard Quality of Life Questionnaire for Allergic Rhinitis (JRQLQ No. 1). The allocation officer confirmed that there were no significant differences between the assigned groups in terms of other indicators as well.

[0116] <Pollen dispersal amount> For the amount of cedar and cypress pollen dispersed during the test period, we used data from Chiyoda Ward, Tokyo, which is publicly available from the Tokyo Metropolitan Government Bureau of Public Health and Medical Services and is measured using the Durham method.

[0117] <Analysis of Results> For the analysis items, the primary endpoint was the Japanese Standard Quality of Life Questionnaire for Allergic Rhinitis (JRQLQ No. 1), and the secondary endpoints included classification of the severity of allergic rhinitis symptoms and assessment of effectiveness (assessment of treatment effectiveness), classification of the degree of local findings, and a survey of eye and nose symptoms using subject diaries. For statistical analysis, the numerical values ​​of the test results were compiled into a cumulative table using Microsoft Office Excel 2016 (Microsoft Corp.), and the mean or median, standard deviation, standard error, maximum value, and minimum value were calculated as basic statistics. The numerical values ​​used in the analysis were the measured values ​​and the change from before intake. Each test item obtained as categorical data was compiled at each test time point. Statistical analysis was performed using appropriate statistical analysis software such as SAS (SAS 9.4) or SPSS (Statistics26), and for all tests, a two-tailed 5% significance level was used, and a 10% trend level was used. In the group comparisons between the test food intake group and the placebo intake group at each test, an unpaired t-test was performed on parametric data, and a Mann-Whitney U test was performed on nonparametric data. All unpaired t-tests were performed using Student's t-test assuming equal variances. For the statistical analysis of efficacy (treatment effect), the number of people in each group who experienced worsening, no change, improvement, marked improvement, or disappearance was tallied. Fisher's exact test was performed if the minimum frequency was less than 5, and Pearson's chi-squared test was performed if the minimum frequency was 5 or greater.

[0118] <Survey Methods and Data Analysis Methods> The subjects' self-reported symptoms were investigated using the Japanese Standard Quality of Life Questionnaire for Allergic Rhinitis (JRQLQ No. 1), in accordance with the 2020 edition of the Rhinitis Allergy Diagnostic Guidelines, focusing on "severity of nasal and ocular symptoms," "QOL questions," and "overall condition." Participants were asked to rate the severity of their own subjective nasal and ocular symptoms on a five-point scale: 0: no symptoms, 1: mild, 2: moderately severe, 3: severe, and 4: very severe, for the following symptoms: runny nose, sneezing, nasal congestion, itchy nose, itchy eyes, and watery eyes. In addition, as part of the "QOL Questionnaire," participants were asked to answer 17 items on a 5-point scale: "0 None (No)," "1 Mild," "2 Somewhat Severe," "3 Severe," and "4 Very Severe." Furthermore, as part of the "Overall Condition" questionnaire, participants were asked to describe their overall condition over the past 1-2 weeks, including symptoms, lifestyle, and feelings, using a face scale ranging from "0 Cheerful" to "4 Want to cry." The data was compiled by totaling the scores for the 6 questions on "Nasal and Eye Symptoms" and the 17 questions on "QOL (Quality of Life) Questionnaires." Furthermore, questions 1-5 of the "QOL Questionnaires" were categorized as "Daily Life," questions 6-7 as "Outdoor Activities," questions 8-10 as "Social Life," question 11 as "Sleep," questions 12-13 as "Physical," and questions 14-17 as "Mental Life," and the scores were compiled for each domain. "Overall State" was compiled using a score value from 0 to 4. Measurements were taken every two weeks.

[0119] The severity of allergic rhinitis symptoms was classified according to the 2020 Guidelines for the Diagnosis of Allergic Rhinitis, based on a combination of sneezing or runny nose and the severity of nasal congestion. These symptoms were evaluated by an otolaryngologist on a five-point scale: "most severe," "severe," "moderate," "mild," and "asymptomatic." The scores were then compiled using the following criteria: "Most severe: 4 points," "Severe: 3 points," "Moderate: 2 points," "Mild: 1 point," and "Asymptomatic: 0 points." The effectiveness of the treatment in improving allergic rhinitis symptoms was assessed by comparing the severity classification of allergic rhinitis symptoms and evaluating them on a five-point scale: "worsening," "no change," "improvement," "marked improvement," and "disappearance." Measurements were taken every four weeks.

[0120] The classification of local findings by otolaryngologists was based on intranasal evaluation using rhinoscopy. Specifically, the swelling of the inferior turbinate mucosa, the color of the inferior turbinate mucosa, the amount of watery secretion, and the symptoms of nasal discharge were observed. Each item was evaluated on a four-point scale from "+++" to "-", and scored as follows: "+++: 4 points", "++: 3 points", "+: 2 points", and "-: 1 point". Measurements were taken every four weeks.

[0121] The results of the survey on the subjects' self-reported symptoms were evaluated on a daily basis according to the 2020 Nasal Allergy Diagnostic Guidelines, with the severity of "sneezing," "runny nose," "nasal congestion," "itchy eyes," and "watery eyes (epiphora)" being assessed on a five-point scale: "most severe," "severe," "moderate," "mild," and "asymptomatic." The scores were then assigned as follows: "Most severe: 4 points," "Severe: 3 points," "Moderate: 2 points," "Mild: 1 point," and "Asymptomatic: 0 points." The average score was calculated every four weeks.

[0122] <Result> This study began with 60 participants in each group, for a total of 120 participants. However, due to trial discontinuation and exclusion from analysis, the analysis included 54 participants in the L.paracasei KW3110 intake group and 53 participants in the placebo intake group, for a total of 107 participants. The mean age of the participants was 42.2 ± 1.7 years in the L.paracasei KW3110 intake group and 44.6 ± 1.8 years in the placebo intake group. During the test period, the pollen dispersal situation for cedar and cypress trees in Chiyoda Ward, Tokyo, began on February 13th (four weeks before ingestion) (1 grain / cm²). 2 (The above) Dispersion continued until just before the end of the trial in May. The peak of dispersal occurred in mid-March, just eight weeks before ingestion (Figure 1). In the following results, the values ​​in the table are shown as mean ± standard error. The table shows the absolute value of the score and the amount of change in score compared to before intake. Comparison with pre-intake levels was performed using the Wilcoxon signed-rank test. The symbols in the table mean the following: †: p<0.10, *: p<0.05, **: p<0.01, ***: p<0.001. Group comparisons at each time point were performed using the Mann-Whitney U test. The symbols in the table mean the following: §: p<0.10, #: p<0.05, ##: p<0.01.

[0123] The results of the Japanese Standard QOL Questionnaire regarding the severity of eye and nasal symptoms and the degree of impairment to daily life are shown in Tables 4, 5, 6, and 7. In the L. paracasei KW3110 intake group, the changes in "nasal symptoms" and "outdoor activities" at week 4 of intake were significantly lower than in the placebo intake group (p<0.05). In addition, the measured values ​​for "outdoor activities" were significantly lower at weeks 2 and 4 of intake (p<0.05, p<0.01).

[0124] Tables 8 and 9 show the results of the severity classification of allergic rhinitis symptoms in the subjects. In the L. paracasei KW3110 intake group, the changes in the "sneezing attack or rhinorrhea score" and "severity score" at 4 weeks of intake were significantly lower than in the placebo intake group (p<0.05).

[0125] Tables 10 and 11 show the results of the assessment of the improvement effect based on changes in the severity classification of allergic rhinitis symptoms. In the 4-week period of intake, when a significant improvement in the severity classification of allergic rhinitis symptoms was observed, a significant improvement effect was observed in the L. paracasei KW3110 intake group when comparing the number of cases classified as "worsening" and "unchanged."

[0126] Tables 12 and 13 show the results of intranasal cavity evaluations by otolaryngologists. In the L. paracasei KW3110 intake group, the measured value of "swelling of the inferior turbinate mucosa" at 4 weeks of intake was significantly lower than in the placebo intake group (p<0.05).

[0127] The results of the eye and nose symptom survey using subject diaries are shown in Tables 14, 15, 16, and 17. In the L. paracasei KW3110 intake group, the measured value and change in "nasal discharge" at 8 weeks of intake were significantly lower than in the placebo intake group (p<0.05).

[0128] From the above results, it was confirmed that ingesting lactic acid bacteria or a composition containing them has an effect of improving eye and nasal symptoms and / or preventing their onset or worsening, and in particular, ingesting L. paracasei KW3110 continuously for 28 days or more, starting before pollen dispersal, is suitably effective in preventing rhinitis symptoms and reducing symptoms.

[0129] [Table 4] [Table 5] [Table 6] [Table 7] [Table 8] [Table 9] [Table 10] Table 11 Table 12 Table 13 Table 14 Table 15 Table 16 Table 17 < / h1> < / h1> < / h1> < / h1> < / h7> < / h1> < / h6> < / h7> < / h5> < / g1> < / g1> < / g1> < / g1> < / g1> < / g1> < / g1> < / g1> < / g1> < / g1> < / f1> < / f1> < / f1> < / f1> < / f1> < / f1> < / f1> < / f1> < / f1> < / f1> < / e1> < / e1> < / e1> < / e1> < / e1> < / e1> < / e1> < / e1> < / e1> < / d1> < / d1> < / d1> < / d1> < / d1> < / d1> < / d1> < / d1> < / d1> < / c1> < / c1> < / c1> < / c1> < / c1> < / c1> < / c1> < / c1> < / c1> < / c1> < / c1> < / c1> < / b1> < / b1> < / b1> < / b1> < / b1> < / b1> < / b1> < / b1> < / b1> < / b1> < / b1> < / b1> < / a1> < / a1> < / a1> < / a1> < / a1> < / a1> < / a1> < / a1> < / a1>

Claims

1. A composition containing lactic acid bacteria for the improvement of eye and / or nasal symptoms and / or for the prevention of their onset or worsening.

2. The composition according to claim 1, wherein the symptoms are symptoms of outdoor and / or outdoor living.

3. The composition according to claim 1, wherein the aforementioned eye and / or nasal symptoms are sneezing fits and / or runny nose.

4. The composition according to claim 1, wherein the improvement of the aforementioned symptoms is the alleviation of discomfort.

5. The composition according to claim 1, wherein the aforementioned eye and / or nasal symptoms are eye and / or nasal symptoms caused by hay fever.

6. 5.0 x 10 per day for humans １０ pcs or more 3.0×10 １１ The composition according to any one of claims 1 to 5, characterized in that it is used so that the lactic acid bacteria of a certain number or less are administered orally.

7. The composition according to any one of claims 1 to 5, characterized in that it is used to be administered orally for a period of 28 days or more from 28 days before the day on which pollen dispersal begins and from the day on which pollen dispersal begins.

8. The maximum daily pollen count measured by the Durham method from the start of administration to day 28 of administration was 1 grain / cm³. ２ More than 220 pieces / cm ２ The composition according to any one of claims 1 to 5, characterized in that it is used to be administered orally over the following period.

9. A composition according to any one of claims 1 to 5, for administration to a person suffering from mild to moderate allergic ophthalmorhinoitis.

10. The composition according to any one of claims 1 to 5, wherein the lactic acid bacteria is Lactobacillus paracasei.

11. The composition according to any one of claims 1 to 5, wherein the lactic acid bacteria is Lactobacillus paracasei KW3110.

12. A composition according to any one of claims 1 to 5, which is a food composition or a pharmaceutical composition.

Images